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G-quadruplex ligands, which can intercalate the G-quadruplex structures, have been 
studied as a strategy for indirect inhibition of telomerase activity, alongside targeting other 
G-quadruplexes found in other genes, including oncogenes. The scope of G-quadruplex 
ligands as cancer targeting drugs is particularly high as there more than 350000 DNA 
sequences within the human genome that can be targeted. In light of this, several small 
molecules have been introduced, which can induce and stabilise G-quadruplexes, which 
are classified as new drug agents for cancer therapy.  This thesis looks at the synthesis of 
suitably functionalised polyaromatic compounds to achieve this stabilisation. 
Deoxyribonucleic acid (DNA) in our cells contains the instructions for all aspects of life, from 
cell division to immune responses. The discoveries and structural determination of DNA, 
leading to the human genome project, provides a great resource for genetic understanding. 
The pairing of nuclear bases is typically represented as Watson-Crick. When DNA is 
chemically changed, disruption to cell processes occurs. Cancer is one outcome of this 
damage, where DNA is damaged to a point where cell cycle control is incapacitated. One 
key aspect of cancer is that cells lose the ability to undergo apoptosis. Telomeres are 
integral structures present in the DNA of eukaryotic cells. They consist of regions of DNA 
motifs that are repeated throughout the structure. These conserved motifs contain an 
abundance of Guanine in sequences of 3-4 repeat units. These Guanine units make up the 
Guanine tetrad structures that allow the telomere to function as genomic stabiliser and 
protective agent against DNA damage or cross chromosome fusion such that all telomeres 
have a single stranded Guanine motif overhang at the 3’ end of the chromosome.   Telomere 
length will usually dictate the lifespan of a cell, however in cancer cells we see this 
mechanism for programmed cell death, hijacked by the expression of telomerase, which 
extends telomere length and inhibits programmed cell death. The well-established principle 
behind the development of G quadruplex ligands is that inhibition of telomerase, which isn’t 
expressed in healthy cells, can selectively facilitate apoptosis of cancerous cells. G-





their propensity to associate with themselves and structures that are similar which will 
intercalate. Because of this, small molecules that intercalate within the structure and 
stabilise them within DNA have targeted G-quadruplexes. This stabilised DNA G-
quadruplex structure will then inhibit the division of the cell through prevention of 
unwrapping and recognition of regulation regions and telomeric regions, which are normally 
cleaved off . 
In this research we aimed to make a number of G-quadruplex ligands to specifically target 
this inhibition and show activity against the HeLa cancer cell line. Throughout the research 
we synthesised several G-quadruplex ligands with different synthetic methodologies. Our 
success with these ligands was mainly achieved with imine couplings and these compounds 
showed cytotoxicity to HeLa cells. Compounds that showed cytotoxicity were further 
analysed for drug G-quadruplex interaction by 1D, 1H NMR titration experiments. Five of 









°C                      degree Celsius 
δ  chemical shift in parts per million 
ΔH                     enthalpy change 
ΔG0                              Gibbs free energy change 
A549                  adenocarcinomic human alveolar basal epithelial cells 
ALT                        alternative lengthening of telomeres 
BCL-2                B-cell lymphoma 2 
BMH-21             RNA polymerase I inhibitor 
BMSG-SH-3      12 tetra-substituted naphthalene diimide 
bp                      base pairs 
br  broad 
BRACO-19        3, 6, 9-tri-substituted acridine; 9-[4-(N, N-dimethylamino) phenylamino]-3, 6-bis (3-       
pyrrolodinopropionamido) acridine 
CD                     circular dichroism  
c-Kit                   receptor tyrosine kinase protein 
d  doublet 
DCM  dichloromethane 
dd  doublet of doublets 
DIBAL                diisobutylaluminium hydride 
DIPEA               N,N-diisopropylethylamine 
DMEM               Dulbecco Modified Eagle’s Medium 
DMF  dimethyl formamide 
DMS                  dimethyl sulfate 
DMSO  dimethyl sulfoxide 
DPPP                1,3-Bis(diphenylphosphino)propane 
ds                      double-stranded 
EDCI  1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
eq  equivalent 
Et3N                   triethylamine 
EtOAc  ethyl acetate 
G                       guanine  
G4P                   G4 formation potentials  
G4(s)                 G-quadruplex(es) 
G-G                   guanine-guanine 





G-tetrad             guanine-tetrad 
G-tract               guanine-tract  
G-C                    guanine- cysteine 
GISTs                gastrointestinal stromal tumours 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide 
hexafluorophospate 
HIF1α              hypoxia-inducible factor 1 
HIV                    human immunodeficiency virus 
HR MS              high resolution mass spectrometry 
HSV-1               herpes simplex virus-1 
IC50                    half maximal inhibitory concentration 
IR              infra-red  
m              multiplet 
Me              methyl 
MeOH              methanol 
MMQ3               quinacridine 
mRNA               messenger RNA  
MYC                  c-MYC, V-myc myelocytomatosis viral oncogene homolog 
m/z              mass to charge ratio 
NDI                    naphthalene diimide 
NMR              nuclear magnetic resonance 
NOESY             nuclear overhauser effect spectroscopy 
PDGF-A            platelet-derived growth factor subunit A  
Phen-DC3         trifluoromethanesulfonate 
PIPER               N,N’-bis[2-(1-piperidino)- ethyl]-3,4,9,10-perylenetetracarboxylic diimide 
POT1                protection of Telomeres 1 
ppm              parts per million 
q              quartet 
QSAR                quantitative structure-activity relationship 
Rf              retention factor 
RHPS4               pentacyclic acridine 
RNA                  ribonucleic acid 
rt              room temperature 
SD                     standard deviation 
SEM                  standard error of mean 
ss                      single-stranded 





TERT                telomerase reverse transcriptase 
THF              tetrahydrofuran 
TLC              thin layer chromatography 
Tm                    melting temperature 
TMPyP4            5,10,15,20-tetrakis-(N-methyl-4-pyridyl)porphine 
TRF2                 telomeric repeat-binding factor 2 
UV-Vis               ultraviolet-visible 
UXF1138L         uterus carcinoma cell line 
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Normal development and growth of organisms is dependent on appropriate and regulated 
cell division. The term homeostasis is used where in normal cells this describes the 
regulation between cell growth, division and the rate at which cells enter apoptosis or stay 
in senescence. In cancer cells, the regulatory elements which dictate this homeostasis is 
hijacked and leads primarily to cells growing and dividing out of control with a loss of ability 
to enter apoptosis (1).  The definition of when cells becomes cancerous is when the rules 
of cell division are not followed by the affected cell, which also leads to the increased 
chances of further genetic mutation and further loss of regulation. This loss of regulation 
makes the cells that are affected grow and push out on tissues around them with no 
restriction in cell growth elicited by messages from exterior tissues (1). 
Healthy cells have several mechanisms that try to prevent damage or mutation in gene 
coding sequences present in the DNA. Most of these are built into the genome itself such 
as the presence of introns, which act as non-encoding DNA. Therefore, when a mutation 
does occur, this makes no difference (silent mutation). Alongside this, the way DNA is 
transcribed and translated means that when a mutation occurs in the coding region (exon), 
then a missense or nonsense mutation will occur. Either this is where an amino acid will be 
changed, or a stop message will be received respectively. However, one of the most 
important properties of the genome, which mitigates damage to DNA, is the presence of 
genomic structures on the end of chromosomes called telomeres. In healthy cells, the 
telomeres act as life span determinants for the cell as with each replication 50-200 base 
pairs are removed from the telomeric region (2). As the telomeres get shorter, the cell will 
eventually enter apoptosis when the non-telomeric DNA starts to shorten during cell 
replication. We see that the regulation of cell growth and life span of the cell maintained by 
the length of the telomeric region within the healthy cells with an absence of co-regulators 
or maintenance enzymes. The point where the cells stop dividing and enter a senescent 
state is call the Hayflick limit with apoptosis shortly afterwards (3).  




The shortening of telomeres and the DNA is seen in most healthy cells but there are 
exceptions in stem cells and germline cells. This characteristic is in cancer cells, as 
telomeres do not shorten with continued and unregulated cell division and is a senescence 
state (4). In cancer cells the key component that maintains the length of telomeres during 
cell division is an enzyme called telomerase and its activity is also used as a biomarker for 
cancer diagnosis (5) (6). Telomeres have G-quadruplex structures present within them and 
are in transcription regulation genes, specifically seen in genes that when overly expressed 
are markers of cancer, if these structures are stabilised or blocked then over expression 
can be inhibited.  
1.1 Discovery of G-quadruplex structures 
 
G-quadruplexes (G4) became biologically relevant in the 1980s mostly based on the 
seminal work undertaken by Dr. Elizabeth Blackburn which showed telomeric DNA forms 
non-Watson-Crick guanine-guanine base-paired intramolecular DNA structures. This 
discovery led to increased research interest and initiated interest in the field of G-quadruplex 
research. Previously, the idea of G-quadruplexes was suggested by Bang in 1910 through 
work with guanylic acid (7), however the structure was only evidenced in the 1950s and 
1960s where the G-quadruplex structure was observed through X-ray diffraction and optical 
properties. Since these discoveries the formation of G-quadruplexes in vitro, in cellulo and 
in vivo has been successfully performed. This allows for the identification of possible 
sequences in the human genome that could form G-quadruplexes.  
1.1.1 G-quadruplex formation 
 
G-quadruplexes are nucleic acid, secondary structures that consist of three or four 
(tetramolecular) single strands. These four- stranded structures differ from the typical 
duplex model of DNA. G-quadruplex DNA structures comprise of stacked G-tetrads, square-
planar phases of four guanines, associated by cyclic Hoogesteen hydrogen bonding 
(termed G-quartets or G-tetrads), as an alternative to the Watson-Crick hydrogen binding 
in a B-DNA duplex. The guanine bonds within a G-tetrad possess either a syn or anti 




glycosidic conformation. These conformations are adopted in a G-strand-directional way, 
with the tetrad guanines attaching through parallel G-strands, therefore embracing the same 
glycosidic compliance; those from antiparallel G-strands obtain the inverse. These G-
quadruplexes can be modified with one, two (8), or four-G-rich strands and are shown in 
Figure 1. Despite the unusual discovery of guanine-rich DNA solutions forming gelatinous 
aggregates in 1910 (9), it wasn’t until 1962 that their composition was determined after 
Gellert et al. using crystallographic methods, suggested that these gel aggregates were 
formed from planar guanine tetramers, resulting in stacks of cyclic (tetrametric) 
arrangements (9). 
The configuration of these tetramolecular structures and their stabilities are associated with 
monovalent cations, especially with K+ and Na+ that form bonds with the eight 
electronegative oxygen molecules (Figure 1) of the adjoining stacked G-quartets (10) (11). 
Since K+ and Na+ are the primary cations in-vivo, G-quadruplex generation is preferred 
under physiological conditions. A Guanine-rich DNA sequence may embrace distinctive 
structures within the occurrence of various cations. The K+ ion conformation is thought to 
be more biologically and naturally applicable, due to its higher intracellular absorption (~140 
mM) in comparison with the Na+ ion (5–15 mM). The actual position of cations between G-
tetrads depends on the properties of these ions: Na+ particles are detected in a wide variety 
of geometries, K+ particles are constantly equidistant within every tetramolecular pattern. 
Generally, K+ ions are favoured over Na+ as K+ has a superior coordination with eight 
guanine oxygen as well as considerably decreased dehydration energy (11). The 
subsequent discovery of guanine-rich sequences, builds an understanding of the 
fundamental, underlying repetitive motif of telomeric DNA observed at the end point of all 








G-quadruplexes can embrace a diverse variety of structures and topologies, when 
compared to duplex nucleic acids that exhibit relative uniformity. Various G-quadruplexes 
have been observed and confirmed by biophysical techniques, particularly by CD (Circular 
Dichroism Fluorescent assays) and IR spectroscopy (Infrared spectroscopy).  
Every G-quadruplex shares a common key element that consists of stacked G-quartets 
within the core of their structures; this includes interior core ion channels as well as four 
grooves that can occupy varying dimensions (Figure 1). The diversity within the varying 
dimensions occurs due to a number of different circumstances. These include:  
Figure 1  Illustration of G-quadruplex structures from simple square-planar arrangement of four 
guanines connected by Hoogsteen hydrogen bonding shown by dotted lines followed by the 
tetrameric and dimeric G-quadruplex structures. The blue dots in the intermolecular G-quadruplex 
structures and intramolecular G-quadruplex structures represent cations (K+ or Na+). That stabilize 
G-quadruplexes by coordinating with the electronegative carbonyl oxygen atoms of adjacent G-
tetrads. Reproduced from Yang, D., & Okamoto, K. (2010). Structural insights into G-quadruplexes: 
towards new anticancer drugs. Future medicinal chemistry, 2(4), 619-646.(14). 
 




(1) inconsistencies and variabilities of the loop length and the arrangement of sequences,  
(2) sequence variances of the length of G-tracts where in most cases they are non-
equivalent and,  
(3) the influences and impacts of monovalent ions within the centre of the channel.  
Little interest was given to  G-quadruplexes up until the early 1990’s. From the 1990’s NMR 
(14) and X-ray crystallographic techniques (14) elucidated the nature of G-quartets leading 
to greater interest in the area of G-quadruplex research.  
Considerable interest has been shown in intramolecular G-quadruplexes that are formed 
from single-stranded DNA. G-quadruplexes have been the subject of considerable 
investigation, in no small part due to their ability to form telomeres at the ends of DNA 
strands and within oncogene promoter sequences seen in Figure 1. In 1985, Blackburn et 
al. made researchers aware of both the presence and importance of telomeres and how 
they are associated with cancer (15). From that point onwards, numerous approaches have 
been developed and evaluated in order to achieve a clinical application. Researchers have 
attempted to reach clinical anti-cancer goals in terms of human telomere reverse 
transcriptase (hTERT) and G-quadruplex targeting ligands.  
Telomerase enzymes preserve the length of telomeres, allowing cancer cells to become 
“immortal”. Within promoter regions and 5’-untranslated regions, the formation of G-
quadruplexes adjusts the translation of many oncogenes. In addition, the formation of G-
quadruplexes encourages genomic instability (a distinctive characteristic enabling tumour 
development) during the cellular replication stage. Due to the effect G-quadruplexes being 
persistent in cancer cells, their structures are seen as important drug targets in anti-tumour 
therapeutics as seen in Figure 3 (16). 











1.1.2 G-Quadruplex Formation in the Human Telomere 
 
G-quadruplex  arrangements can be found at different positions along the chromosome, 
however, initially  G-quadruplex forming nucleotide sequences (as part of the telomere) 
were thought to protect chromosomes from deterioration. Telomeres are repetitive regions 
located at the end of chromosomes; these are found in all organisms that exhibit linear 
chromosomes. During mitosis, DNA sequences lose 50-200 bases per replication and 
telomeres are thought to be sacrificial sequences, preventing the loss of base pairs 
occurring to the exons of chromosomes (17)(18). 
1.1.3 Action of Telomerase 
 
Telomerase enzymes are activated in a large portion of human cancer cells (80-85%) (19); 
playing an important role in controlling the malignant phenotype (where cells divide out of 
control and invade nearby tissues) by maintaining integrity and telomere length (8). 
Telomerase activity in human cancer cells can be inhibited by the G-rich sequences of 
telomeric human DNA. These sequences have a strong ability to form DNA G-quadruplex 
secondary structures. It is very likely that the formation of telomere ends involves 
intramolecular G-quadruplex molecules; however, their formation may also be associated 
with a process known as a T-loop invasion complex.  T-loop configuration includes single 
Figure 2 Telomeres shortening mechanism when cells go through normal mitosis.  
 




stranded telomere DNA interfering with the double stranded portion of the telomere causing 
a displacement of the G-quadruplex structures and their base pairs with the complimentary 
strand (20).  
These secondary G-tetrad structures have shown to hinder telomerase enzyme activity, 
which makes these intramolecular telomeric structures an active target for cancer therapy 
as well as potential target of medical pathways (Figure 3) (8). Recent investigations 
suggested that these secondary DNA G4 compounds interfere with and distort the telomere 
capping as well as activating apoptosis (Figure 3) (8). Telomeric DNA is known to be linked 
with a numerous variety of protein structures which interferes with processes of telomere 
maintenance and interrupts the telomere capping process, e.g. TRF2 (Telomeric repeat-
binding factor 2) and Pot1 (Protection Of Telomeres). This may be identified as DNA 
damage, which therefore promptly activates apoptotic pathways in the absence of telomere 
shortening (8). In addition to this, G-quadruplexes have also been known to inhibit the 
alternative lengthening of telomeres (ALT) pathways. ALT is a maintenance mechanism 
that is telomerase independent, which maintains the stability of telomeres occurring in 
∼15% of cancer cells in which telomerase is not activated (8).  
Figure 3 Illustration of the inhibition of telomerase by G-quadruplex ligands followed by drug 
mediated blocking of telomere capping by ligands. Adapted from Yang, D., & Okamoto, K. (2010). 
Structural insights into G-quadruplexes: towards new anticancer drugs. Future medicinal chemistry, 
2(4), 619-646. (14). 














1.1.4 G-quadruplex DNA as a target for anticancer drugs    
 
G-quadruplex DNA structures led to a new approach to anticancer drug design and 
development through the targeting of secondary DNA structures (8). In 1997, Sun et al. 
(21), stated that these secondary DNA structures, when stabilised could possibly be 
clinically curative active compounds within damaged cells. Specifically, small molecules that 
target G-quadruplex DNA structures alongside hindering telomerase. Small molecule 
targeting G-quadruplex structures lead compounds were determined from the discovery of 





Figure 4 Illustration of telomerase enzyme activity in cancer and normal cells 




1.1.5 G-quadruplex compounds as cancer targeting drugs  
 
Stabilisation of G-quadruplex structures by binding to a ligand molecule predominantly 
occurs through pi-pi stacking and electronic interactions to the external face of the G-
quadruplex DNA structures (22). Investigated and tested G-quadruplex ligands include 
BRACO-19 2 (acridine derivative) (23),  telomestatin 3 (macrocylic natural product) (24),   
RHPS4 (pentacyclic acridine) 4 (25), MMQ3(quinacridine) 5, (26)  Mn (III)- porphyrin 6, (27) 
BMSG-SH-3,12 (tetra-substituted naphthalene diimide) 7 (Figure 5) (28)and triazoles 8(29) 
(30). All these ligands possess a large aromatic planar area alongside a short non-polar 
alkyl chain with a charged group. These structural motifs have been shown to be effective 
for a G-quadruplex ligand by improving selectivity by aromatic-aromatic connection and 
ionic interactions between the ligand and external face of G-quadruplex structure 
respectively (31)(22). Initial research was mainly focused on improving G-quadruplex 
ligands selectivity for non-Watson-Crick base paired DNA (22)(32)(33). The first telomere 
interacting molecular structure was found to be 2,6-diamidoanthraquinone derivatives 
synthesised by Neidle et al (34). Subsequently, TMPyP4 9 and telomestatin 3 were found 
to bind to G-quadruplexes (35) (36) leading to the rapid development of selective G4 ligands 
through improved methods and analytical techniques to investigate the specific binding 
profile of each drug. There are now G-quadruplex ligands, available commercially, which 
have almost completely selective binding to G-quadruplex structures. These include 
BRACO19 2 (23), pyridostatin 10 (37), Phen-DC3 11 (38), L2H2-6OTD 12 (39), and L1H1-











Figure 5 Skeletal structures of G-quadruplex binding ligands 1-8 
 
It has been demonstrated that G-quadruplexes are present in genes that have been shown 
to be overexpressed in several different cancers, the stabilisation of which can effectively 
act as a switch for these genes (41). These studies and investigations of synthetic small 
molecules for G-quadruplex binding have led to the promise of G-quadruplex ligands as a 
targeted approach to cancer therapy. An example of a G-quadruplex stabiliser would be 
that of pyridostatin 10 (2) G-quadruplex ligands are designed to only target the transcription 
elements of genes that are overexpressed in cancer therefore, it is expected to select for 
cancer rather than for healthy cells (42). The advantages seen by G-quadruplexes include 
the time required for inhibition, which has been shown to show anti-tumour activity after 
one-month (43).There are also several mechanisms of action, from telomere shortening 
mechanism and stabilisation of gene targets for cancer, these properties make this method 
selective. Toxicity has also been shown to be lower than other chemotherapeutic treatments 
for example BRACO-19 2 compared to Doxorubin (44). We also see a new generation of 
ligands deriving from acridine derivatives, which allow for further interaction within the 




grooves of G-quadruplex structures. This additional interaction activity increases the activity 
and the selectivity (45). Validation of G-quadruplex ligands in the use of cancer therapy was 
demonstrated in investigation of the c-myc oncogene (2). The cytotoxicity decrease of these 
ligands can be explained by the low toxic effects of telomerase inhibitors compared to other 
drugs when dosed appropriately over a long time. 
Pyridostatin (PDS)
           10
Phen-DC3 
        11
       
L2H2-6OTD
       12
L1H1-7OTD
        13  
Figure 6 Skeletal structures of G-quadruplex binding ligands 10-13. 
1.2 Gene targets of G-quadruplex ligands 
 
Genes within DNA contain several different regions including a promoter region an encoding 
region and terminating region. The promoter regions of several proto-oncogenes have 
shown to form G-quadruplex structures, suggesting possible targets for G-quadruplex 
ligands. Specific proto-oncogenes include c-MYC, c-KIT, BCL-2, k-RAS, VEGF, HIF1α, and 
PDGF-A (46)(47)(48)(49)(50)(51).This gives another pathway for cancer drug discovery in 
that drugs can be synthesised to target promoter regions instead of telomeres 
(52)(53)(54)(55)(56). 
The proto-oncogenes listed above have a wide variety of functions, however it was shown 
that the G-quadruplex structures in the promoter regions were crucial for transcription 




regulation. One of these proto-oncogenes (c-KIT) translates to a tyrosine kinase receptor 
(c-KIT) that is present within the membrane(56)(57). The c-KIT receptor when activated will 
phosphorylate downstream targets, which will promote cell growth, proliferation, survival 
and migration (58). If this receptor is overexpressed it leads to excessive activations of cell 
growth factors, which is indicated in several cancers such as gastrointestinal stromal 
tumours (GISTs), pancreatic cancer, melanoma and haematological neoplastic diseases 
(59)(60).There are several research studies that have demonstrated c-KIT kinase activity 
inhibition in vivo and in vitro via G-quadruplex ligands (61)(62). In these studies, there was,  
a major limitation to clinical use, which was resistance to treatment. Resistance could arise 
through mutations in the promoter regions, stopping drug binding, which prevents selective 
inhibition of the kinase when the c-KIT gene is activated within the genome (57). This 
limitation means that other methods must be implemented which avoid the issues above. 
One such method is multi-target therapy or the use of G-quadruplex ligands to stabilize G-
quadruplexes within the c-Kit promoter regions. Specifically, for the c-KIT, they should target 
the three guanine (G)-rich regions in the proximal promoter (47)(58)(63). Research done on 
this has shown that there is a reduction of c-KIT tyrosine kinase receptor expression when 
G-quadruplex structures are stabilized by small molecules (64)(65)(66)(67)(68)(69)(70). 
This strategy can be considered as an alternative to overcome mutation-related resistance 
which prevents traditional gene targeting drugs from functioning.   
An example of small molecules working in this way was tested by Mazzini et al. 2019 who 
showed that BMH-21 (RNA polymerase I inhibitor) and its analogue BA-41 did not 
intercalate DNA but did bind to telomeres and c-MYC promoter G-quadruplexes (71). 
This specific example is also complemented by other research showing that stabilization by 
small molecules of G4 in genes including hTERT (72), KRAS (73)(74), BCL2 (75), and 
VEGF (76), led to inducing tumour apoptosis. 
 
 






It has been demonstrated that Vascular Endothelial Growth Factor (VEGF) protein 
overexpression in tumour cells induce the development of new vasculature 
(neovascularization). Neovascularization in tumour cells is induced by several VEGF 
proteins, specifically VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and PIGF. Regulation of 
these proteins in eukaryotic cells is predominantly done at the point of transcription from 
DNA to mRNA rather than translation to protein (77)(78). 
Evidence of the regulation site of VEGF being at a promoter region in DNA was shown by 
a reporter assay system on several cancer cell lines. This work showed that regulation was 
controlled by a sequence at -85 to -50 base pairs (bp) relative to the transcription start site. 
This sequence was made up of five motifs of >3 consecutive guanine residues (79)(80). 
This suggests that the guanine tetrad structures formed at these sequences are the 
regulatory elements of VEGF (76). This makes VEGF a promising target for malignant 
tumour selective therapies with several antibody drugs previously being approved for the 
treatment of solid tumours (81)(82). 
It has been described previously how the intercalation of TMPyP4 9 and telemostatin 3 with 
these G4 structures in-vitro has demonstrated the breaking of intra strand interactions to 
form ssDNA from duplex DNA, which subsequently gives a stable structure for the G4 
structures (76). Testing of the regulation of VEGF at this site was done through the use of 
a universal G4 interacting molecule, Se2SAP, which demonstrated active suppression of 
several adenocarcinoma cell lines’ VEGF expression (83). This study clearly showed the 
promise that ligands which bind selectively at this promoter region can have for regulation 
of VEGF expression and therefore mitigate the neovascularisation potential of tumour cells.  
This treatment option could thereby give a way of slowing tumour maturation and reduce 
chances of metastasis and further complications.  
 






The KIT tyrosine kinase is involved in several cancer types in humans. These include 
gastro-intestinal cancers specifically which demonstrates that the improper regulation of 
expression is a key factor in the progeny of the disease type (34)(84)(85). It has been 
detailed that at position -87 to -109 bps and -140 and -160 bps upstream of the initiator site 
for the c-KIT gene there are G4 structures present (86). Studies on targeting these G4 
structures for regulation of the c-KIT genes has been limited to demonstrating correlations 
between the binding of small molecules to the c-KIT G4 structures and respective inhibition 
of the KIT tyrosine kinase expression (68)(64)(67)(69)(88)(87). 
1.2.3 BCL-2  
 
The apoptosis regulating protein B-cell lymphoma 2 (BCL-2), is a double action protein that 
either inhibits (anti-apoptotic) or induces (pro-apoptotic) apoptosis. This property is why it 
is involved in several cancers, ranging from melanomas to carcinomas (88). A region of the 
promoter at -1490 and -1451 upstream of the P1 promoter has shown that the 
intramolecular G4’s would form at G-rich domains within this region (89). It was identified 
by Hurley et al that there were three G4 motifs at the 5’ end, middle and 3’ end of the region 
(90).These three G4 structures were thoroughly characterised by DMS foot printing, 
Polymerase stop assays and NMR spectroscopy. This characterised the most stable G4 
structure as being made up of mixed parallel/anti-parallel G4, containing two lateral and one 
external loop. (90) (91) (48). Interaction of TMPyP4 9 with these structures has previously 
been investigated in in-vitro solution (92) however this study was limited by the absence of 
clarity of the function biologically of BCL-2 G4 structures in vivo. Despite this it has been 
shown that BCL2 dependent pathways contain non defined roles for G4 structures. 
Evidence for these roles has been shown through reduced transcription to mRNA in the 
presence of G4 binding small molecule 12459 14 (seen in Figure 7), a triazine derivative, 
which correlated to the induction of apoptosis in A549 cells through interaction with 
mitochondrion-related pathways (93). 









The DNA binding transcriptional activator MYB, which is encoded by the proto-oncogene c-
MYC, is integral in controlling proliferation and differentiation of hematopoietic progenitor 
cells. Its expression is highest at the early stage of development and gradually decreases 
as differentiation proceeds (94). The discovery of c-myb in humans was found through the 
identification of its analogue in avian myeloblastosis virus and E26 (v-myb) through genomic 
matching (95). Its status as a proto-oncogene is evidenced by the development of 
haematological cancers and adenocarcinomas, when expression is high through 
differentiation, and not regulated where it decreases over the time of differentiation (96) 
(97)(98)(99)(100). Regulation of the levels of mRNA produced from c-myb is reliant on 
several other transcription activators and inhibitors that are specific to each cell type and 
cell stage (101)(102)(103)(104)(105)(106). As such, regulatory elements in the promoter 
region are seen at -17bp to the transcription start site, where a guanine rich region is found 
which forms parallel G4 structures (105)(107)(108). The regulatory properties of this region 
for the promoter were demonstrated through targeted deletion of parts of the guanine rich 
region which inhibited the formation of dimerized G4 structures. This deletion led to 
enhanced promoter activity and a higher expression of MYB, which suggests that the G4 
structures regulated transcription through an inhibitory method of action (negative 
regulation) on the c-myb promoter (105). It has also been shown that the transcription factor 
Myc-associated zinc finger protein may bind to this G4-structure and stabilise the G4 which 
in turn inhibits MYB expression. 




1.3  Quarfloxin  
 
Quarfloxin 15 (Figure 8) is one of the G-quadruplex compounds, which progressed to Phase 
II clinical trials stage as a single-agent treatment for neuroendocrine/carcinoid tumours. 
Quarfloxin 15 is also referred to as CX-3543 or itarnafloxin (109). This G-quadruplex 
compound was initially derived from a group of fluoroquinolones, which were presented to 
have dual topoisomerase II and G-quadruplex interactions (109). Cylene Pharmaceuticals 
halted research into topoisomerase II activity and increased research into compounds 
selective for G-quadruplex structures (109). The selectivity of Quarfloxin 15 to G-quadruplex 
DNA arises from its selective uptake into the nucleolus of cancer cells. No significant 
toxicities were observed for Quarfloxin 15, which means apoptosis occurs to cancer cells 
not to normal cells. Even though Quarfloxin was designed originally for targeting the c-MYC 
promoter G-quadruplex, it has also shown that it has higher selectivity in contrast to 
TMPyP4 9 for all-parallel G-quadruplex structures (109). Even though it has been shown to 
have higher selectivity for G-quadruplex structures it has also been found to concentrate in 
the nucleolus and has an inhibitory effect on Pol I transcription (109). The inhibition of RNA 
polymerase I (Pol I) can be explained by the disruption of the G-quadruplex–nucleolin 
complexes through Quarfloxin 15 binding, which in turn leads to cellular redistribution of 
nucleolin into the nucleoplasm. Quarfloxin 15 was shown to bind to most G-quadruplexes 
and disrupt all but one of the nucleolin–DNA complexes (109).  
In 2013, Quarfloxin 15 was licenced to TetraGene by Cylene Pharmaceuticals on an 
exclusive, worldwide basis. Cylene Pharmaceuticals however, ceased operations in 2013 
due to the high albumin binding seen which caused disruption to blood transport of active 
compounds.  





Figure 8 Skeletal structure of Quarfloxin 15 
 
1.4  BRACO-19 
 
BRACO-19, 3, 6, 9-tri-substituted acridine; 9-[4-(N, N-dimethylamino) phenylamino]-3, 6-bis 
(3-pyrrolodinopropionamido) acridine 2 (Figure 9) is derived from trisubstituted acridine, 
through modification of position 3 and 6 with pyrrolidine and position 9 with a tertiary amine, 
which showed direct targeting of telomeres. Computer modelling was used to find 
compounds which interacted with the three grooves of G-quadruplexes, and stacked on the 
terminal G-quartet, leading to the design of BRACO-19 2 (110). The cytotoxicity of BRACO 
19 2 is very low (IC50 values 1-3 μM in UXF1138L uterus carcinoma cell line(23)) and it has 
a much higher G-quadruplex-binding specificity and telomerase-inhibitory activity than its 
parent disubstituted acridine.  It was then shown that BRACO19 2 inhibits the catalytic 
function of telomerase in human cancer cells and it also destabilizes the telomere capping 
complex (110). BRACO-19 has been demonstrated as a powerful anti-cancer agent in 
studies on prostate cancer xenografts (111) and human breast cancer cells (110). Because 
of its demonstrated anti-cancer properties BRACO-19 2 is a heavily researched G-
quadruplex ligand. The synthesis of BRACO-19 2 was achieved after a long and arduous 
research programme that thoroughly tested the medicinal chemistry required of the 
molecule. This research begun with an acridine moiety as the planar core (chromophore) 
different to other G4 ligands. This was done as Read et al. showed that this chromophore 
had higher binding activity than other cores specially anthraquinone (112)(34). This higher 
activity can be explained by the nitrogen atom within the acridine that when protonated 




increases the electron deficiency giving greater interaction with G-quadruplexes (113). The 
use of molecular modelling and structure-activity relationship techniques gave insight into 
how the acridine moiety could be added to, to give bi- and tri-substituted derivatives that 
could give higher binding activity selective for G-quadruplexes (114)(115). BRACO-19 2 
and its derivatives are a class of compounds that have a central planar chromophore that 
selects for the G-tetrads present in G4 through hydrophobic interactions between 
hydrophobic core and the centre of the G-tetrads.  The grooves formed in the G-tetrad are 
selected for by the addition of a functional tertiary amine which when protonated at 
physiological pH will form hydrogen bonds with the backbone oxygens (116). As previously 
mentioned BRACO-19 2 was selected from evaluated molecules because of its 
advantageous properties.  
BRACO-19
2  
Figure 9 Skeletal structure of BRACO-19 2. 
 
1.5  TMPyP4  
                          
Porphyrin derived compounds have been selected for study as G-quadruplex ligands as 
they have preferential properties as a G-quadruplex intercalators. This includes their 
molecular size which allows for transport into the nucleus, a planar core for interactions with 
stacked G-tetrads alongside hydrophobicity before any modifications are made. The 
addition of positive charges to the porphyrin ring can be achieved with several types of tetra 
modifications but here we focus on the modification through the addition of four N-methyl-
4-pyridyl groups to form a 5,10,15,20-tetrakis-(N-methyl-4-pyridyl)porphine (TMPyP4) 9 




(117). Despite initial hopes for TMPyP4 9 as a cancer targeting drug, where biophysical 
studies showed stacking and stabilization of antiparallel and parallel structures there was 
only mild selectivity for quadruplex over duplex DNA (118). Because of this it is primarily 
used as a research tool as when the pyridyl groups are bound at position 2 rather than 4, it 
loses any activity. This gives a very useful negative control with an almost identical structure 
(119)(120). Despite this TMPyP4 15 has demonstrated human telomerase inhibition, 
alongside a second target in the proto-oncogene c-myc where expression has been shown 
to be downregulated (121). There are also several other c-myc-regulated genes, which 
contain G4 structures, that have shown downregulation with the administration of TMPyP4 
9. These findings resulted in the reduction in tumour growth and increased survival time 
within several in vivo antitumor models (122). 
 
Figure 10 Skeletal structure of TMPyP4 9 
 
1.6  Perylenes and naphthalene diimides  
       
This class contains a variety of substitutions to the heptacyclic aromatic planar core. This 
aromatic planar core is required for selectivity as it interact to the G-tetrads. Substitutions 
on the aromatic core are used to add protonated side chains which will bind to the external 
grooves of the G-quadruplex structures. From the substituted derivatives several key 
properties were identified which gave greater activity. These included the basicity which 
stops aggregations of the ligands by preventing pi-pi stacking of the chromophore. There is 




also a consideration for the distance of the bonding between the aromatic core and the 
substituted nitrogen which selects for G4 structures and increases water solubility (123). 
The perylene structure that has shown the greatest potential through demonstrated 
stabilization G4 structures in telomeres is PIPER 1 (Figure 5), N,N’-bis[2-(1-piperidino)- 
ethyl]-3,4,9,10-perylenetetracarboxylic diimide (124). This has led to PIPER being used as 
a lead compound for further drug discoveries(125). Drugs that can stabilise G-quadruplexes 
in telomeres like PIPER 1 (Figure 5) can be expected to shorten telomeres, reduce 
tumorigenicity, cell proliferation and senescence (126). Despite these promising findings it 
was suggested that modulating the ability to recognise DNA conformations by altering the 
planar core would lead to more promising compounds. One class of compounds derived 
from this work was the naphthalene diimide (NDI) 17 derivatives which suggested that a 
reduced aromatic core of at least four rings was sufficient to select for G-quadruplex 
structures (127). With NDI 17 there is also the advantage of additional sides for substitution 
with four available, compared to PIPER’S 1 two. This increase can allow for increased G4 
affinity through addition of more G4 structure stabilizing moieties. NDI 17 derivatives have 
been tested on MCF-7 and A549 cell lines which are cancerous, the results showed that 
these compounds can, in low micromolar concentrations, interact with telomere G-
quadruplex structures and inhibits telomerase activity (128).  The introduction of quinone 
methides precursors to the planar core gave increased alkylating properties towards G4 
structures (129)(130). These modified NDI 17 structures increased selectivity for G-
quadruplex structures through reversible and irreversible binding to telomeres (131). This 
greater selectivity led to inhibition of telomerase activity of different cancer cell lines 
(132)(133)(134). X-ray crystallography work done by Neidle et al. showed how NDI 17 
ligands form complexes with telomeric structures. They showed that the complex was 
stoichiometric between ligand and G-quadruplex which suggests that direct interactions 
between grooves and side chains were achieved and binding affinity was high (135)(136). 
With the use of molecular modelling and further crystallographic techniques NDI structures 




17 (seen in Figure 11) can be further optimized through medicinal chemistry investigations 
which will improve the specific pharmacological profile (137)(42). 
 
Figure 11 Skeletal structure of naphthalene diimide (NID) 17, modifications have been seen on the 
R groups and one of the phenyl rings to give G4 alkylating properties. 
1.7  Anthracene derivatives  
 
Anthracene derivatives with nitrogen rich groups added are required for interaction with 
quadruplex DNA which requires planar nitrogen rich species which allow for intercalation 
within the G-quadruplexes and binding to the anionic phosphate back bone of DNA. 
Anthracene 18 (seen in Figure 12) possesses the correct geometry to sit between the G-
tetrads through its hydrophobic core, but lacks the hydrophilic elements, which allows for 
greater water solubility. Selectivity for G-quadruplexes by anthracene derivatives has been 
demonstrated through longer linking between the hydrophobic core and hydrophilic 
elements, addition of terpyridine metal complexes and through screening of different 
hydrophilic arms for hydrogen bonding (138). 
 
Figure 12 Skeletal structure of anthracene 18. 
 




1.8  Other potential G-quadruplex targeting drugs 
 
Various levels of selectivity and potency in binding to G-quadruplexes has been seen in 
quindoline derivatives, the diamidoanthraquinones (110). 
Moreover, aptamers, short single-stranded DNA structures which selectively bind to targets 
(protein, peptide, DNA), were found to be good target molecules for G-quadruplexes, due 
to their size, high selectivity and stability making aptamers an ideal drug candidate for 
cancer therapy.  A cancer selective treatment with antiproliferative activity against a wide 
range of malignant cell types entered Phase I trials in September 2003, AS1411 (Antisoma 
plc, London, UK) inhibits the growth of malignant cells by inducing apoptosis. AS1411, It 
also has went through a Phase 2 study in August 2008. However, Antisoma has since halted 
their research and they have become an investment company named Sarossa.  
For G-quadruplex ligands selectivity and low toxicity is required for drugs to progress to 
Stage II Clinical Trials. For selectivity we need to have an extended planar structure to aid 
intercalation of stacked Hoogsteen bonded G-tetrads.  
1.9  Ligands that disrupts G-quadruplex folding 
 
Disruption of G4 structures by small molecules can be achieved in several different ways 
through intercalation at different parts of the structure or formation of different structures 
through molecular interactions. An example is in the previously detailed porphyrin derivative 
TMPyP4 9 that, specifically in the Fragile X FMR1 gene, disrupts the bimolecular G4 
structure and decreases the thermic stability of the structure as shown by melting 
temperature investigations (139). TMPyP4 9 has also been shown to unfold G4 structures 
in the mRNA of MT3 endopeptidases, which leads to an increase in expression of this gene 
in cancer cells (140). Alongside this investigation of TMPyP4 9, studies done by Waller et 
al, which used a triarylpyridine 19 (Figure 13) as a scaffold for designing G4 targeting small 
molecules, identified a derivative that disrupting G4 structures within c-kit 1 and c-kit-2 
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genes at 50µM concentrations (141). Interestingly it was also demonstrated that other small 
molecules using this scaffolding were shown to stabilise G4 structures (142).  
CD spectroscopy of G4/ligand complexes containing an anthrathiophenedione derivative 
20 (Figure 13) by Kaluzhy et al. showed unfolding of telomeric DNA structures in the same 
way as spectra of thermal denaturing of telomeric DNA structures showed it (143). However, 
the mechanism of how G4’s unfolding occurs after interaction of these derivatives in the 
binding site has not been elucidated as of yet but understanding this would allow for more 
intuitive design of G4 ligands. 
 
Figure 13 G-quadruplex ligands that previously demonstrated ability to induce unfolding of G4 
structures. 
Recent addition to research on these structures was done by O'Hagan et al. who discovered 
stiff-stilbene derivative 21 (Figure 13) that, when introduced to Tel23 (d[TAG3(T2AG3)3]) 
induces unfolding of its hybrid sodium form (144). Contrary to this action the stilbene 
derivative also stabilizes the hybrid potassium form of Tel23(d[TAG3(T2AG3)3]). Molecular 
modelling has been used to illustrate what the lowest energy form of the ligand is which 
allows for characterisation of the most feasible binding site within the structure and how the 
unfolding commences. These investigations led to the suggestion that the ligand binds 
initially to the G4 grooves and then intercalates with the G4 structure, thus leading to 
distortion of hydrogen bonds with the tetrad structure. The central stilbene scaffold also has 
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an additional useful property; in that its photochemical potential allows for the use of light 
as an activating agent when introduced into tumours therefore giving greater potential for 
selectivity. The use of different wavelengths of light for example 365/385 nm allows for 
switch from E to Z conformations, allowing for changes in potential activity. 
1.10 G-quadruplexes in viruses 
 
Sequences that form G-quadruplex structures are present not only in humans but also other 
eukaryotic cells, and they are seen in prokaryotic cells. The G-quadruplex structures will be 
expected to be found in the promoter regions of exon genes as transcription regulators. 
These regulatory systems have even been found to be developed in viruses. Specifically, 
G4 structures have been observed in the genomes of Human immunodeficiency Virus (HIV) 
(145) and Herpes Simplex Virus-1 (HSV-1) (146) which implies the G4 are important in 
transcription regulation of replication genes, recombination and regulation of gene 
expressions (145).  Small molecules designed through medicinal chemistry investigations 
for hydrophobic intercalation with G-tetrads and anionic grooves could be used for inhibition 
of the mechanisms in place for viral replication. This means that infectivity and pathogenesis 
of viruses could be reduced. To test this hypothesis, several investigations into G4 ligands, 
which target the HIV genome have been undertaken (145)(147). The drug discovery 
strategy for this purpose has, in the last two decades, moved more to the development of 
aptamers that form G4 structures that can be recognized by HIV proteins which has been 
suggested by several research papers. This has led to the synthesis of a magnitude of 
guanine rich aptamers that are promising lead compounds for anti-HIV drug discovery 
(145)(148)(149)(150). 
Specific proteins that have been shown to interact with these proposed aptamers are 
envelope proteins, integrase and reverse transcriptase. The design of these have been 
done by several approaches, classed as rational or randomized fragments design.  
G4 structure regions are found in the genome of HPV through the identification of guanine 
rich sequences (151). These guanine rich sequences are only found in eight HPVs, however 
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a possible aptamer target that is present in most HPVs is the viral protein E1, that modulates 
the transcription, replication of the genome in its function as a helicase. The reason it is a 
possible target is its similarity to SV40 TAg which is a well-known dominant acting 
oncoprotein helicase (152), this means that E1 could present activity for unfolding G4 
structures. G4 structure sequences are in in the long control region of HPV52 and HPV58, 
alongside the promoter region for the L2 protein in HPV57 and E1 and 4 in HPV32/42 and 
HPV3/9/25 respectively suggesting roles in transcription and the production of viral proteins 
from alternative splicing. Targeting of these genes could be one of the reasons why 
BRACO-19 2 and TMPy4P 9 have shown HIV-1 replication inhibition (153)(154) where 
BRACO-19 2 acts as inhibitor of reverse transcription and post integration by the viral 
promoters.  Both of these functions can be explained by the intercalation with G4 structures 
present in genes, promoter regions and proteins specific for transcription regulation. 
This inhibition of HIV-1 by BRACO-19 2, which is targeted in the promoter region of 
specifically LTR, works by intercalation of G-quadruplex structures in LTR-II and LTR-III. 
This intercalation, rather than blocking function or unwrapping, actually forms an additional 
G-quadruplex structure called LTR-IV as more LTR-IV is formed through increasing 
concentration of BRACO-19 2, we see a reduced LTR promoter activity. This action was 
illustrated by the demonstration of no activity in mutants, which were unable to form G-
quadruplex structures. Short term and long-term in vivo testing showed the potential of 
BRACO-19 2 where the acridine derivative was able through G-quadruplex intercalation 
and transcription regulation to reduce the viral load to negligible levels (155). 
We have seen the use of BRACO-19 2 in the modulation of the regulation of HIV infection 
however BRACO-19s 2 activity in viruses was first shown in the Epstein-Barr virus (EBV). 
In this study, the function, and biochemical properties of Epstein-Barr virus nuclear antigen 
(EBNA1) which is conversed in all EBV-related malignancies, was investigated. The 
investigation showed that the G-quadruplex structures in the viral RNA was stabilised by 
BRACO-19, this suggests that during infection the number of genome copies were reduced 
in Raji cells. Norseen et al. saw the inhibition of dependent DNA replication and transcription 
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regulation in EBNA2 and EBNA3A. These findings give an indication that G-quadruplex 
ligands can inhibit specific functions of EBNA1 related to viral DNA replication (156). 
The stabilization of G-quadruplex structures in telomeric DNA by BRACO-19 2 was 
assessed in cells infected by human herpes virus (HHV-6A). The treatment gave 50% 
reduction of integration into the chromosome. Investigation of the effects on replication and 
expression of genes are future work in HHV-6 research (157).  
Another virus that has been analysed for G-quadruplex structure and their position is 
Hepatitis-B virus (HBV). This analysis showed that G-quadruplexes may have a regulatory 
function. The use of BRACO-19 2 is currently limited to being a reference compound in G4 
structure research because of its poor permeability across biological membranes (158), 
however it has shown by use in a luciferase reporter assay that G-quadruplex have a 
transcription regulation role in HBV (159). 
Another small molecule besides BRACO-19 2 that has been shown to have a similar mode 
of action is TMPyP4 9, which induces G4 structures formation within standard Watson crick 
base pairing and stabilization within the NEF coding region in HIV-1. TMPyP4 has also been 
shown to inhibit the viral activity of the TZM-bl (HeLa cell derivative) reporter cell line 
(specific to nef-dependent HIV-1 replication), with dose dependent correlations seen (154). 
It has also been demonstrated to block viral replication in lurkat-derived T-cell lines which 
have latent HIV-1 infection. Work done by Bambara et al. showed the rate of cell 
death/apoptosis was positively correlated with antiviral activity, with enhancement of this 
effect achieved through links to DNA damage repair inhibitors (155). TMPyP4 9 was also 
found to be a promising anti-viral agent for the Hepatitis C virus as RNA G-quadruplexes 
were demonstrated to be stabilized and fluorescent reporter genes were used to show the 
inhibition of HCV C gene expression. To corroborate these findings, introduction of TMPyP4 
15 into a HCV infected cell culture led to a decrease of viral RNA levels dependent on the 
concentration of TMPyP4 9 used (160). Besides the regulatory mechanisms inhibited by 
TMPyP4 9 it has also been used to determine the roles of G-quadruplexes in the L gene of 
EBOV. 




1.11 G-quadruplexes in bacteria 
 
The genome of prokaryotes (bacteria) exists in a very different state to that of eukaryotes, 
such that the genomic data does not reside in a separate organelle (nucleus) but is stored 
in uncondensed circular chromosomes and plasmids that can transfer between cells 
through transduction (161). Since the genomic material is not protected in a nucleus and 
condensed to form protective chromosomes via protein interactions, the stability of bacterial 
genomes comes from secondary structures that form in the bacterial genomes (162). This 
stability is epitomised by G4 structures that are present throughout, which have shown 
slower unfolding kinetics to even duplex DNA in Eukaryotic cells (163).  
Despite these findings not many studies have been done investigating the role of genomic 
stabilising G4 structures for bacterial survival and virulence of specific bacteria strains (164). 
A function of G4 structures that has been demonstrated by Pooja et al was that amino acid 
biosynthesis and signal transduction are negatively regulated by the presence of G4 
structures within the encoding gene (165). We see a distinct difference in the number of 
studies relating to G4 structures with prokaryotes (166), when compared to eukaryotic 
studies (167) which means that there is a lack of clarity on several aspects of the G4 
structures within prokaryotic DNA. Despite the obvious need for G4 structures within 
prokaryotic DNA for stability, we see a great variability in the GC (Guanine-Cysteine) 
content, which is a determining factor in whether G4 structures will form (168), between 
different bacterial genomes 17-75% (169). There has also been shown in the order 
Deinococcales a bias of G4 forming motifs around the transcription start sites of genes 
suggesting a role in regulation of expression (170). Looking at variability of GC (Guanine-
Cysteine) content more closely we can elucidate another role for G4 structures. Specifically, 
in Thermus aquaticus we see one of the highest GC contents at 68%, which would allow 
for maintenance of duplex DNA even at higher temperatures (171). We also see a large 
number of G4 forming sequences upstream of the NasT gene in Paracoccus denitrificans 
which is exposed to toxicity from digestion of NO3- (172). The genes that participate in the 
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host-pathogen interactions of Stretoccocus pneumoniae have also been shown to contain 
G4 structure motifs within their genomic sequence (164). These findings clearly 
demonstrate the importance of G4 structures within bacteria that experience unique DNA 
damaging environment, alongside the role played within circular DNA in chloroplasts and 
mitochondria which were evolutionarily taken from prokaryotic organisms. Mitochondrial 
DNA’s reliance on G4 structures has been illustrated in several papers using several 
different assays and analytical techniques (173)(174)(175). Chloroplasts have also shown 
G4 like structures within their regulatory domains of chloroplast DNA (176). 
1.12  Synthesis of G-quadruplex ligands  
 
1.12.1 Anthraquinones, Porphyrins and Acridines derivatives 
 
Derivatives in the class of anthraquinones (177) porphyrins and acridines were the first 
small molecules synthesised to intercalate G-quadruplex structures within telomeres to 
indirectly inhibit telomerase. Specifically, disubstituted acridines were synthesised followed 
by the addition of another substitution to give trisubstituted acridines(178). Porphyrins (179) 
were also synthesised alongside anthraquinones and trisubstituted acridines to give greater 
efficacy to intercalation of telomeres leading to regulation of telomerase.  
In this class of G-quadruplex ligands BRACO-19 2, a 3,6,9-trisubstiuted derivative of 
acridine showed the greatest potential for therapeutic use. Neidle et al. showed that 
BRACO-19 2 (180) could inhibit cancerous cell division in vivo and in vitro at sub micromolar 
concentrations (23).  
3,6,9-trisubstiuted acridine derivatives 29 as shown in Scheme 1 (23), are synthesised via 
an acridone precursor which has a chloro group added at the 9 position to form compound 
28 of the acridine structure through treatment with POCl3. Substitution of this chloro then 
takes place to form a final acridine derivative 29. Interest in these derivatives has increased 
through the demonstration of a 10X selectivity between G-quadruplex structures (181). 
 





Scheme 1.  General synthetic scheme for 3,6,9-trisubstituted acridine 29 derivatives. (DCM = 
dichloromethane, DIPEA = N,N-diisopropylethylamine) (182). 
1.12.2 Natural products showing telomerase inhibition  
 
It has been shown that berberine 29 (183) and telomestatin 3 (184) have human telomerase 
inhibiting properties. Telomestatin 3 is the focus of most research as it has a greater 
inhibition of telomerase. Streptomyces anulatus produces telomestatin 3 and it was isolated 
after wide spanning screening process for inhibitors of telomerase (185). Telomestatin 3 
has demonstrated at sub nanomolar concentrations to have inhibitory activity.  Its structure 
which contains two methyloxazoles which are linked to five oxazoles separated by a 
thiazoline ring was characterised allowing for biosynthesis and total synthesis to be 
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understood. This understanding allowed the absolute configuration to be shown as R (186).  
Multiple human tumours including in the brain (187) blood (188) and bone marrow (189) 
have been shown to be inhibited by the action of telomestatin 3 in in vivo and in vitro studies.  
Scheme 2 Synthetic scheme example which was previously reported by Marco Franceschin 13-[3-
(1-piperidino)propyl]berberine (piperidino-berberine) (190). 
A key intermediate of this synthetic strategy was obtained through the use of acetonyl-
berberine. Afterwards, the acetonyl group was displaced with 1,3diiodopropane 32, 
following this the iodine atom was substituted with piperidine to give the desired side chain 
(Scheme 2). According to the research by Marco Franceshin et al (190), compared to 
berberine 30, piperidino-berberine 34 showed a greater stabilization of G-quadruplex 
structures and a greater telomerase inhibition as shown through the use of TRAP assay 
(190). 
1.12.3 Perylene derivatives 
 
PIPER 1 structure was first discovered to show telomerase inhibition in 1998 by Hurley et 
al through a NMR study. In the report, PIPER 1 was shown to bind to G-quadruplex and 
Chapter 1- Introduction 
46 
 
inhibit telomerase, however the structure was found to stacks on the G-tetrad closest to the 
3’ end rather than intercalating between the Guanine residue in the G-quadruplex (125). 
However, the initial synthesis, by Fedoroff et al (125), of PIPER 1 was achieved through 
3,4,9,10-perylenetetracarboxylic dianhyride mixing with 1-(2-aminoethyl) piperidine in DMA 
and 1,4-dioxane seen in Scheme 3. This procedure was adapted from the DAPER synthesis 
which was done by Zhi-Ren LiuR and L. Ril in 1996 (191). 
 
Scheme 3 Mechanism for PIPER synthesis (125). 
1.12.4 Methods to synthesise Quarfloxin  
 
Quarfloxin is one of the fluoroquinolone derivatives which consists of different conjugated 
aromatic systems alongside many other side chains designed and synthesised by Cylene 
Pharmaceuticals (109). Quarfloxin was the most promising fluoroquinolone derivative which 
was found to be extremely selective for c-myc G-quadruplex structures. 
Looking at the compound synthesis, which was done by Whitten et al (192) and patented, 
they started preparing the substituted benzoaxanize analog using 2,3,4,5-
tetrafluorobenzoic acid 37 in methylene chloride with addition of oxalyl chloride seen in 
Scheme 4. The afforded acid chloride oil was then converted to keto ester 39. 




Scheme 4 Generating tetrafluoroketoester 39 from 2,3,4,5-tetrafluorobenzoic acid 37 using oxaxlyl 
chloride first, then triethylorthoformate. 
Tetrafluoroketoester 39 was then converted to enamine using triethylorthoformate and 
acetic anhydride. This reaction was followed by adding potassium carbonate to the solution 
of enamine to make difluoroester seen in Scheme 5. The resulted ester group after addition 
of N-Boc-3-(2-pyrazino) pyrrolidine was successfully converted to pyrazine ester 43. 
 
Scheme 5 Illustrated reaction schemes representing the conversion of tetrafluoroketoester 39 to 
pyrazine ester 43. 
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This reaction step then was followed by coupling the 2-(2-aminoethyl)-l-methylpyrrolidine 
with pyrazine ester 43, with addition of aluminium chloride to make the amide product which 
was named as Quarfloxin 15.  
 
Scheme 6 Amide formation 15 using aluminium chloride to catalyse reaction between 2-(2-
aminoethyl)-l-methylpyrrolidine 44 and pyrazine ester 43. 
 
1.12.5 Heck reaction 
 
Based on the work done by Le Gresley et al (193), it was anticipated that a relatively 
straightforward synthesis of a range of novel acrylamides and their coupling via Heck 
reaction to brominated derivatives of the aforementioned classes of structure would afford 
a diverse range of potential G-quadruplex ligands, suitable for in vitro screening. The Heck 
reaction was discovered by T. Mizoroki and R.F Heck in the 1970’s. Since its discovery, the 
Heck reaction has come to be one of the most commonly used palladium-catalysed carbon-
carbon bond forming reactions for organic synthesis. The Heck reactions versatility comes 
from its ability to tolerate functional groups e.g. alcohols, carboxylic acids, esters and dienes 
(194). Because of this, several intermediates in drug discovery involve the Heck Reaction. 
An example is the active anti-cancer drug, taxol, which has an intramolecular Heck Reaction 
within its synthesis. 
The Heck reaction consists of a soluble Pd catalyst, phosphine ligand and a base making 
up a homegenous medium. Precipitation of the Pd catalyst is prevented through stabilsation 
by the phosphine ligand, in aryl bromide reactions the tri-o-tolylphosphine, P(o-Tol)3 was 
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found to be more effective than the first ligand used PPh3. Catalytic regeneration is achieved 
via elimination of HX in the catalytic site by the bases within the medium (195). The Heck 
reactions C-C bond forming is via migratory insertion rather than  reductive elimination like 
other palladium-catalysed cross-coupling reaction’s. The traditional mechanism for the 
Heck reaction is presented in Figure 14. 
 
 









1.13 Characterisation techniques for G-quadruplexes 
 
1.13.1 CD (Circular dichroism) spectroscopy 
 
Several analytical techniques have been used to characterise G-quadruplex structures, 
differentiating between parallel/anti-parallel and different hybrid structures of G-quadruplex 
DNA. The most commonly used technique is Circular dichroism (CD) spectroscopy, as it 
allows for analysis of active chiral centres and specific spectra for each type of structural 
feature. This allows for identification of loop regions,parallel/antiparallel strands and is 
heavily used in protein research as the peptide bonds are optically active. Despite 
correlations between the G4 folding and final structure and CD spectra not being validated 
as of yet, we can still use the technique as a tool to empirically say whether one structure 
is different to another or comparable to a reference structure. Since CD spectra have been 
assigned for complete characterisation of many G4 structures in solution and validated via 
NMR and X-Ray crystallography, there is a precedence in place for this characterisation 
approach. An investigation of the G-rich DNA oligomer, MYC Pu27-Mer which is in the 
NHEIII1 region of MYC for example demonstrated a CD spectrum which had a broad peak 
at 240nm, with a large sharp peak at 260nm and a smaller peak at 212nm (196). This 
spectrum represents an intramolecular parallel G4 structure indicative of the MYC Pu27-
Mer DNA oligomer as validated by NMR spectroscopy (197). We can also elucidate from 
CD spectra with similar features the presence of a hybrid parallel/anti-parallel G4 structure 
when a broad positive shoulder peak is seen between 280nm and 300nm. These spectral 
features are seen when the G-quadruplex of the oligomer Pu39WT in BCL-2 suggesting its 
structure, then further validated by NMR (90)(91). Thrombin binding aptamer (TBA) 
displayed a chair-type anti-parallel G-quadruplex structure as validated by X-ray 
crystallography and NMR (198). In the CD spectra a large positive peak was seen at 290nm, 
a smaller peak was seen at 246nm and a negative peak at 265nm, which is indicative from 
previous spectral analysis of the validated structure of TBA (108)(199). From these studies 
with several different analytical techniques alongside the use of other techniques, such as 
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the CD melting and UV absorbance at 295nm, other properties of G4 structures can be 
elucidated. These properties include the Tm, ΔH, and ΔG0, which are crucial to determine 
the stability of the G4 structures, specifically in human telemetric G4s (200)(201)(202)(203). 
1.13.2 NMR (Nuclear Magnetic Resonance) Techniques 
 
The use of Nuclear Magnetic Resonance Spectroscopy (NMR) in the study of small 
molecules, peptide, proteins and nucleic acid structures has been widely used by many 
different types of researchers, from molecular biologists to organic chemists. The 
characterisation of G-quadruplex structures is therefore not surprisingly achieved in a lot of 
studies by a suite of NMR experiments. There are limitations however when we look at 
repeating motifs, which are required for the formation of G-quadruplex structures, as the 
chemical shift differences between the different motif units are not great which raises an 
issue of resolution within the NMR spectra. Ways of reducing the complexity of the spectra 
with either compound-based solutions, e.g. using two-fold or four-fold symmetric structures, 
or NMR techniques that are designed to increase resolution between respective peaks have 
been used. The limitation was highlighted in the first studies of telomeric DNA using NMR, 
which did not give sufficient structural information to fully characterise G4 structures 
however, it did show an abnormality in the structure of telomeric DNA. When the sequence 
d(TTGGGG)4 was used, NMR spectroscopy demonstrated that that the guanine residues 
took part in nonstandard base pairing (G-G) and that several guanines were in the syn 
conformation (204). The syn conformation was identified by Nuclear Overhauser NMR 
spectroscopy (NOESY), which showed a strong NOE effect between the protons of guanine 
at the 8 position (H8) and the HI’ deoxyribose proton describing a short distance between 
the respective protons. Detailed characterisation of a G4 structure via NMR was achieved 
by studies on the oligomer d(GGTTTTTGG), which was previously elucidated to have a 
tetramolecular complex by calorimetric analysis (205)(206). The torsion angles of sequential 
glycosidic bonds were shown by NMR to alternate syn-anti wise for each adjacent guanine 
residue along the strand. This structure was also seen in sequences similar to the studied 
d(GGTTTTTGG), such as d(GGTTTTCGG) (206). Despite the prediction of alternating 
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glycosidic conformations via molecular modelling of the respective guanines that are 
involved in individual G-tetrads, the prediction of Glycosidic torsion angles along the strand 
is lacking. This gap in the knowledge was based upon an assumption that glycosidic 
conformation does not vary along the strand, as models of telomeric DNA structures using 
fibre diffraction analysis showed models structures with this property (207)(208). From the 
initial study using d(GGTTTTTGG) it was demonstrated that multiple conformers were seen 
in the NMR spectra, and that slow exchange was seen relative to the NMR timescale. It was 
also demonstrated that variation in the counter ion present within the tetrad, e.g. Na+ or K+ 
varied the structures formed by telomeric DNA, which also determined the relative stability 
of the structures formed (209). These studies were carried out using the oligomer 
d(TTGGGG)4 and d(TTAGGG)4 with either sodium phosphate or potassium phosphate 
buffers being used to determine the respective counter ion within the G-tetrad. Using the 
imino proton peaks within the spectra it was shown that multiple species of imino protons 
were present between residues at a high concentration, which was required for sensitivity 
of the imino protons. Chemical shift differences in the imino proton peaks for Na + and K+ 
were shown to be significantly different for both oligomers studied, while also demonstrating 
that K+ as a counter ion gave greater stability when compared to Na+. It was impressive 
also to see how thermally stable the K+ forms were with imino protons still being observable 
for the d(TTGGGG)4’ oligomer specifically at 90 degrees. 
1.13.3 X-Ray Crystallography 
 
Studies on the oligomer d(GGGGTTTTGGGG) using both NMR analyses (210)(211) and 
X-ray crystallography (212) illustrated the presence of a G-tetrad core structure along the 
strand. Torsion angles calculated for glycosidic bonds showed alternating syn/anti-syn 
conformation along the residues and specifically in regions related to G-tetrad structures. 
The presence of thymine within the strands create loops at the opposite ends of the G-
tetrad core in a head to tail shape with X-ray crystallography showing the joining of adjacent 
strands which could not be interpreted with only NMR spectroscopy. Resolution limitations 
in NMR which prevent the characterisation of several structural features are revealed by the 
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interpretation of X-Ray crystallographic date. Specifically, it showed that the base geometry 
in G-tetrads is often distorted from the regular square planar arrangement of guanine 
bonding. It also highlights that the guanines are pushed out of the plane of the G-tetrad, 
with the core of the tetrad having an electron density correlating to a bound potassium ion. 
It was shown that the ion is located between the second and third G-tetrad in the core of 
the structure. 
Looking at the different aspects, G-quadruplex ligands are widespread and can be found in 
every part of biology. From cell maintenance in bacteria and virus infected cells to a role in 
the onset of cancer G-quadruplexes have been shown as a key target for therapeutic 
remedies. Many research groups have done work to synthesise and validate G-quadruplex 
ligands. Different classes of G-quadruplex ligands have been developed and been tested 
for anticancer activity. Through the research, many of these ligands were active, however, 
most of them did not show selectivity for G-quadruplex DNA.  From the research only 
BRACO-19 and Quarfloxin went through to clinical trials, however due to their toxicity they 
did not successfully pass the trials. This failure to get passed clinical trials, demonstrate the 
need for more selective and specific compounds to be designed to allow for a new class of 


































The aim of this research was to synthesise a range of G-quadruplex ligands and to build on 
previously synthesised G-quadruplex ligands. These ligands would be designed to have 
lower toxicity compared to current ligands through greater selectivity for G-quadruplex 
structures over duplex DNA. To address this challenge, a series of planar building blocks 
were to be functionalized with a range of amine groups. These amine groups were selected 
based upon the physiological generation of positively charged side chains that would bind 
to the negatively charged phosphates in the ribose backbone in an orientation specific to 
G-quadruplexes. These amine groups were selected based upon the properties previously 
shown to have lower IC50 values in telomerase activity (213). These properties include more 
than two aminoalkyl/amido side chains, length of linker between charged nitrogen atom and 
amide group needs to be two methylene units. In addition to these properties, the chosen 
planar skeleton needs to be close to the width of a G-quartet, to allow attached amine 
groups to improve the binding of the ligand. If the chosen linker includes heterocyclic 
amines, this has been shown to make it a more effective ligand and the position of 
heterocyclic groups within the structure has also been shown to be important (213). Careful 
considerations of these properties allowed the construction of a library of potential G-
quadruplex ligands.  
Our approach to synthesising these ligands was to create a static combinatorial library using 
Heck methodology, EDCI.HCl coupling and reversible imine formation. Building these static 
compounds will generate different types of ligands by the combination of simple building 
blocks with different coupling methodologies. Through this, the most active and stable 
compounds would be chosen to work with.  Heck methodology (Scheme 7) has been used 
by Le Gresley et al. (193) using 9,10-dibromoanthracene 45 seen in Scheme 11, a planar 
lipophilic core that acts as a hydrogen bond donor and acceptor via the branches in the 9 
and 10 positions. This afforded potential ligands for assessment using first 1H DOSY NMR 
and then cell-based assays. In their work, they chose a variety of amine groups which were 
converted to acrylamide using acryloyl chloride, This was then coupled using Pd(OAc)2 to 
make diacrylamide derivatives for evaluation.  





Scheme 7 Heck Coupling of acrylamides to 9,10 – dibromoanthracene. 
 
In addition to this work, Le Gresley et al. endeavored to build dynamic combinatorial libraries 
of G-quadruplex ligands using a conjugate addition (Scheme 8) (214).   























46 R = H
48 R = Me
 
47 R = H
49 R = Me
50 R = 51 R =
 
Scheme 8 Bis-acrylamide derivatives of anthracene synthesized by the Le Gresley group. 
They synthesized and characterized the compounds 46, 47 and 48, then these compounds 
were tested on MCF-7 cancer cell lines and shown to have acceptable Log P values.  
Acrylamide




Figure 15 Graph showing MCF-7 cell populations after 48hrs in the presence of a concentration 
range of 47 (193). 
 
From this work, this anthracene diacrylamide class of G-quadruplex ligand 47 has shown 
sufficient anticancer activity to make this template worthy of further investigation, in terms 
of selectivity for both duplex and G-quadruplex DNA. The aim was also to expand the series 
of G-quadruplex ligands based on the 9,10-dibromoanthracene core and to understand how 
the structure effects the activity through QSAR analysis.  
Where the selected amides were not compatible with Heck coupling conditions, direct 
EDCI.HCl couplings were considered and, towards the end of the project, investigations 
into reversible imine formation to generate a static combinatorial library of potential G-
quadruplex ligands.  
Standard peptide coupling using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI), 
was undertaken, where limitations were observed for Heck coupling conditions, where the 
palladium catalyst can be deactivated under certain conditions where unwanted 
complexation of the palladium catalyst with the acrylamide to be coupled can inhibit the 
catalyst. An example of this is where EDCI coupling could be used after initial acrylate 
formation via Heck reaction and hydrolysis (Scheme 9). 




Scheme 9 Synthetic routes for EDCI coupling 
 
Being reversible and thermodynamically driven imine couplings could allow us to exploit 
selectivity when combining amines with an anthracene aldehyde derivative (Scheme 10). 








Scheme 10 Synthetic route for imine couplings. 
 
In addition to expanding on the anthracene derivatives to optimise binding to G-





















Figure 16 Illustrated structures are the skeleton templates for modification, which were used in this 
research. 
 
The aim was to optimise the synthesis of a range of amide/imine derivatives of the templates 
in Figure 16 to ascertain the best binding motif for the G-quadruplex. Finding the best array 
would then allow us to build a dynamic combinatorial library, an approach to molecular 
design where building blocks construct libraries of complex structures through reversible 
chemical reactions which favour thermodynamically stable structures, of these ligands 
(215). 
After the synthesis of a static library of G-quadruplex ligands, these were to be screened 
for anti-cancer activity through the use of cell culture assays such as, MTT assay, Natural 
Red Assay and Presto Blue assay. Use of multiple assays gives greater validation of results. 
These assays were to be done with HeLa cancer cell lines with positive and negative 
controls to confirm the activity to validate that activity is related to drug (ligand) 
concentration. Statistical analysis (one sample t-test) was then to be used to rank the activity 
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of compounds through their IC50 values and respective R2 values. This would allow us to 
compare the dose response and order of the kinetics. MTT assay assesses the metabolic 
activity of cells by colorimetric assay which determines cell viability (Figure 17). The 
colorimetric assay works through the conversion of tetrazolium to formazan by NAD(P)H-
dependent cellular oxidoreductase enzymes. 
 
Figure 17 Mitochondrial reduction of MTT to blue formazan product. 
 
 
This MTT assay allows measurement of cell proliferation and degree of cytotoxicity from 
added drugs.  
The MTT assay is shown to work through a chemically reductive mechanism, however 
neutral red and presto blue work through a staining and an environmental reductive 
mechanism. These differences would allow us to determine which technique gives the most 
reliable results. Neutral red assay determines the number of viable cells and cytotoxicity of 
drug. The neutral red assay is adapted from histological methodology through staining of 
lysosomes by eurhodin dye which gives a red colour. If cells are killed or made non-viable, 
they cannot absorb the stain into lysosomes, therefore a reduction in neutral red intensity 
















In addition to these two cell assays, Presto blue was used to determine if the cells are alive 
and healthy. Presto blue reagent consists of resazurin-based solution, which, when in a 













Figure 18 Diagram illustrating mechanism of Neutral red assay. 
Figure 19 Diagram illustrating mechanism of Presto blue assay. 
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Following on from this, the compounds that show anti-cancer activity, were further screened 
for G-quadruplex intercalation to measure whether the ligand structure forms through space 
bonds with a telomere G-quadruplex model. This screening was also used to demonstrate 
the likely stoichiometry of ligand to G-quadruplex structure. These insights into structure 
activity relationship give insight into what parts of the ligand structure are important for 
intercalation to G-quadruplex structure and therefore would correlate to an inhibitory effect 
on telomerase. 
Combinations of these analytical techniques will give a wide picture of which ligands are 
best suited for further investigation and modification as drug targets for G-quadruplex 
targeting drugs in cancer therapies.  
Nuclear magnetic resonance (NMR) spectroscopy was selected as the technique to 
investigate the structures formed by model oligonucleotides under physiological conditions 
and screen for interactions of compounds that showed activity against HeLa Cells. NMR 
spectroscopy has been used to assess the synthesised ligands. This was selected owing 
to the numerous validated protocols already in place (216). 
NMR spectroscopy benefits from the ability to study G-quadruplex structures in 
physiological relevant models. Whereas X-Ray crystallography, which is excellent in 
distance measurements and structural characterisation, lacks this benefit. NMR also 
provides detail on kinetics, dynamics, and concentrations, which are powerful tools in the 
classification of G-quadruplex ligands. 
This technique was used to identify structures that bind to the G-tetrad structure and the 
type of binding. Be it the more common stacking on the terminal G-quartet or less common 
binding to the groove of the G-tetrad structure. These binding/stacking mechanisms can be 
determined through the observation of not only the G-tetrad region spectra, but also the 3’- 
and 5’- adjacent nucleotides, which will have major structural changes, if capping or binding 
occurs at these locations, to allow for accommodation of ligands. Analysis of the spectra 
also allows for determination of the exchange kinetics and stoichiometry of each ligand 
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allowing kinetic and dynamics analysis alongside the structural information. This information 
was to help explain the IC50 values determined through cell culture studies. With this 
analysis, however we must remember to highlight the limitations of our G-quadruplex 
oligomer model when comparing to in-vivo telomere G-quadruplex structures and the 
conclusions we can come to. Despite the limitations of model systems, the aim was to allow 
future considerations on structure-based drug designs, with decisions made on what parts 
of the ligand are key and what parts can be optimised for ligand activity and preferential 
binding mode. 
Determination of G-quadruplex structure by NMR from a practical aspect is made simpler 
through the appearance of the imino peaks of guanine at a chemical shift range of 10.5-12 
ppm which is characteristic of G-tetrad formation (Figure 20). These peaks are seen to be 
distinctly separated from other DNA structure imino peaks with high resolution. This means 
that monitoring of these peaks allows for determination of G-tetrad formation and any 
disturbance to these peaks or changes will allow for screening of drug binding interactions. 
We can also determine the number of guanines associated through Hoogsteen hydrogen 
bonded G-tetrads through the number of imino H -1 protons in the 10.5 – 12ppm range. 
These experiments were run in a H2O-D2O solution with water suppression to allow for 
reading of the spectra and interpretation of imino peaks. 
 
Figure 20 Typical imino protons representative of G-tetrad formation. 
The model system used was parallel, tetrameric system to allow for easier identification of 
peaks. The reason for this is that it has been demonstrated that each monomer in the 
tetrameric system will present with the same spectra, therefore giving an amplification of 
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spectra by four rather that giving four overlapped spectra. This simplification of spectra is 
also required, as assignment of added drug will be done to demonstrate changes in 
chemical shift and diffusion coefficients properties of ligands as demonstrated in Figure 21. 
 
Figure 21 DOSY analysis of a mixture of PE (1.0 mg mL−1) and d(TTGGGTT)4 (0.25 mM). The 










Chapter 3 – Results




The aim of this project was to synthesise a library of novel G-quadruplex intercalators based 
on anthracene and other phenyl-rich arrays. The compounds synthesised were based on 
the below structure motifs (Figure 22) with cytotoxicity and their ability to intercalate the G-
quadruplex being evaluated. This evaluation was done using Presto Blue Assay and NMR 
titration techniques with a G-quadruplex aptamer.  
52 53 54
55 56 57  
Figure 22 Templates for G-quadruplex ligand development 52-57. 
A number of anthracene-based diacrylamides were synthesised by Le Gresley et al. (193) 
and they generated a small library of G-quadruplex ligands. This was primarily done via 
coupling of 9,10-dibromoanthracene 45 via the Heck reaction. These acrylamides were 
specifically chosen to provide a greater degree of polar/ hydrogen bond binding to the 
phosphate backbones of quadruplex DNA. Our research was to develop these previously 
synthesised acrylamides and built a larger library of G-quadruplex ligands. 
  




3.1 Synthesis of Acrylamides for the Heck reaction  
 
One of the potential methods for synthesising derivatives for the 52-57 classes of compound 
would be to couple the appropriate acrylamides directly. To enable this, synthesis of a range 
of acrylamides was undertaken. They were synthesised under dry, standard conditions, i.e.  
dry DCM was used as a solvent. 2 eq. of triethylamine and 1 eq. of the amine group were 
then added into DCM. Following this 1.2 eq. of acryloyl chloride was added in a drop wise 
manner over 5 minutes, while the reaction was in an ice bath. The reaction mixture was 
warmed to room temperature and stirred for 1 hour. TLC and NMR were used to monitor 
and characterise the reaction mixture.  
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Figure 24 Amine groups (a-m) to be used the synthesis of acrylamides. 
 
Table 1 Reaction data for acrylamides 59a-h (Figure 24) in coupling reactions with 1 in an 8:1 ratio 
*very low yield was obtained, as products were unable to be separated from the reaction mixture. 
Amine group Acrylamide  Duration/h Yield (%) 
a 59a 72 82.5 
b 59b 72 5 (crude)* 
c 59c 150 5 (crude)* 
d - 72 - 
e - 72 - 
f - 72 - 
g - 72 - 
h - 48 5(crude)* 
 
The amines a-h were chosen based on possessing complimentary binding motifs to the G-
quadruplex and there being literature precedent to support potential anticancer activity e.g.  
piperonylamine contains a benzodioxole ring which is a H-bond acceptor and are found in 
anticancer drug analogues of capsaicin (218), 4-(aminomethyl) pyridine was used because 
of previous literature stating its anticancer activity within certain derivatives which targets 




G-quadruplex DNA (219). Adenine/Guanine/Thymine and Cytosine were chosen, because 
they are nucleic acids groups in human body and there exist potential interactions with G-
quadruplexes through their H bonding in Hoogsteen base-pairing in DNA (219). The amine 
groups j-m were used to synthesise imine derivatives (in section 3.6). 
A representative piperonylamine acrylamide was synthesised  (shown in Figure 25) and 
confirmed using NMR as seen in the assigned spectra at 5.6ppm(H-6), 6.2ppm(H-4) and 
6.3 ppm(H-3); the peaks for the Ha,Hb and Hc of the acrylamide with integrals matching that 
expected. The integrals are calibrated to that of the piperonylamine peaks at 4.3ppm (H-7), 
6.8ppm(H-2),6.9(H-1) ppm and 6ppm(H-5), which have the correct ratio of integrals. 
Figure 25 1D-1H assigned spectra of 59a. 
However, as evidenced by Table 1, some of the amines did not prove amenable to 
conversion into the corresponding acrylamide through coupling to acryloyl chloride.   
Therefore, rather than persist in attempting to synthesise the derivatives 59d-h the decision 
was made to attach those amines directly via carbodiimide coupling from 52. (Figure 22) 
With the piperonylamine acrylamide 59a in hand we proceeded to couple it to 45. However, 
repeated attempts to couple it to 9,10-dibromoanthracene via Heck reaction were 




unsuccessful. This was potentially because of the acidic acetyl group possibly reacting with 
the palladium catalyst or causing deacetylation and deactivation of the catalyst through 
cHeLation. The initial reaction conditions were changed such as changing to Schlenk tube 
from reflux and introducing a new ligand (DPPP (1,3-Bis(diphenylphosphino)propane, 
Triphenylphosphine and Tri(o-tolyl)phosphine).  These changes did not allow the coupling 
of the piperonylamine; therefore, a different synthetic route was chosen. 
After issues with acrylamide coupling to 9,10-dibromoanthracene (shown in Scheme 11). 
We ordered two acrylamides to test the Heck coupling to anthracene. Firstly N-
(butoxymethyl) acrylamide, which was successfully coupled to 9,10-dibromoanthracene 
with the Heck reaction followed by successful coupling of N-(isobutoxymethyl) acrylamide 
to 9,10-dibromoanthracene. For these couplings we used tri-(o)tolyphosphine rather than 
DPPP as the ligand.  
It was possible to source brominated precursors for the general templates 52-57 (Figure 
22) such as 9,10 dibromoanthracene 45 (Scheme 11). This facilitated the direct synthesis 
of a range of acrylamide derivatives of the 52 type using 0.2 eq. of palladium acetate and 
0.2 eq. of phosphine ligand in a Schlenk tube, followed by stirring in DMF 
(Dimethylformamide) for 10 minutes at room temperature to generate the catalyst first. After 
activating the catalyst 8 eq. of trimethylamine and 1 eq. of 9-10-dibromoanthranece 45 were 
added to the reaction mixture, at room temperature, followed by addition of 8 eq. of selected 
acrylamide. The mixture was heated to 90°C for 48 hrs under nitrogen to yield compounds 
of the type 60 (Scheme 11). 















                                                                               













The synthesis of the N-(butoxymethyl) acrylamide (60a) (shown in Figure 26) was validated 
using NMR in (DMSO-d6) as seen in the assigned spectra  at  4.2ppm (H-5) and 8.1ppm 
(H-2), the peaks for the added alkyne bonds with integrals matching that of the expected 
integrals when calibrated to anthracene ring. In addition to this spectrum, N-(butoxymethyl) 
Figure 26 1D-1H and 2D-1H/1H COSY assigned spectra of 60a. 
 




acrylamide had a COSY experiment also run to validate assignments at 0.9ppm (H-9) and 
1.4ppm (H-8) for assigned protons 8 and 9. Moreover, the cross peak at 1.6ppm (H-7) and 
3.5ppm (H-6) for assigned protons for 6 and 7. These assignments validate the integrals 
calculated for the 1D spectrum. 
Despite having synthesised a number of acrylamides for palladium-catalysed coupling, in 
our hands we found the Heck coupling to be largely unsuccessful, affording either 
intractable mixtures, or such poor yields as to make the synthesis of such ligands not viable.  
Faced with difficulties in synthesising some of the more interesting acrylamides and poor 
yields from Heck couplings, it was decided to synthesise the corresponding acrylates and 
hydrolyse them for amide coupling reactions with EDCI.  A Heck coupling of methyl acrylate 
to 9,10-dibromoanthracene was carried out, to build a more stable scaffold for coupling of 
amine groups, followed by hydrolysis of the methyl group to carboxylic acid. This would then 
allow, for example, EDCI.HCl coupling of piperonylamine to the carboxylic acid group to 
form piperonylamine coupled to 9,10-dibromoanthracene 45. 
Successful coupling of methyl acrylate is shown in Figure 27. The assigned spectra consist 
of peaks related to trans alkynes of the methyl acrylate 6.3ppm (J = 16.81 Hz, H-4) and 
8.3ppm (J = 16.25 Hz, H-1). Also, a peak for the methyl group next to the carbonyl group at 
3.9ppm (H-5). The corresponding integrals for these peaks match those expected when 
coupled to 9,10-dibromoanthracene with its peaks seen at 7.3ppm (H-3) and 8.1ppm (H-2). 
Therefore, the next step is hydrolysis of the methyl acrylate group which is shown in Figure 
28. From Figure 28 the carboxylic acid group at 12.2ppm (H-5) alongside the methyl groups 
disappearing at 3.9ppm. Alongside the rest of the coupled product peaks not changing, 
hydrolysis is validated by the presence of the methyl group.  
 





Figure 27 Assigned NMR spectra and structure representing coupled methyl acrylate to 45 (60c). 




Figure 28 Assigned NMR spectra and structure representing hydrolysed structure of 60c (60d). 
3.2 Electrophilic substitution reaction of anthracene  
 
Whilst the novel palladium-coupled substitution of synthesised acrylamides in the case of 
45 was largely unsuccessful, we wanted to investigate the possibility of coupling more than 
two acrylamide groups per aromatic core. This idea was conceived because of the 
properties of the G-quadruplex, specifically the four phosphate ions present in the backbone 
of each parallel tetrad of the G-quadruplex. Our thinking was that three or four ionisable 
amine groups binding to phosphate ions would give greater affinity than two. 
 45 45a  
Scheme 13 Proposed synthetic route for 45a. 
We aimed to synthesise 2,6,9,10-tetrabromoanthracene 45a following the procedure by 
Rosso et al. (220) using a solution of bromine in nitrobenzene with addition of 9,10-




dibromoanthracene. Steric hindrance favoured the addition of bromine atoms to the para 
position relative to the ortho position of each individual aromatic ring in anthracene. This 
favourable addition at the para relative to ortho position of one bromine unit would then 
preferentially promote addition at the para position relative to the first added bromine. This 
reaction did not work as the addition of bromine de-activates the ring. The desired product 
was not synthesised in significant yields, with the predominant products being brominated 
anthracene with substitution on both sides at the ortho position relative to the bonds 
between aromatic rings.  
The reaction protocol was carried out using a Schlenk tube with a separating funnel 
attached for addition of reagents. Firstly, 9,10-dibromoanthracene 45 was added and then 
it was mixed with nitrobenzene (3.5ml). The solution of 9,10-dibromoanthracene in 
nitrobenzene was then heated to 1000C. When the temperature was stable at 100oC, 0.19 
ml bromine in 0.5ml nitrobenzene was added dropwise into reaction mixture through a 
separating funnel. Following the addition of bromine, the reaction mixture was heated up to 
160oC for 5 hrs and then warmed to 200oC for 30mins. After this, it was left to stir at room 
temperature.  TLC analysis was used during the experiment to monitor the reaction. The 
whole reaction was filtered and washed with water followed by DCM (3X15ml) and the 
resulted precipitate was analysed using NMR.  
 A small quantity of bromine was still present in the reaction; therefore, the reaction could 
be quenched by the addition of aqueous sodium dithionite Na2S2O4 (20%,50ml). 
After numerous unsuccessful attempts, varying temperature, duration, and stoichiometry, 
we decided to find a different type of aryl core with 4 or 3 bromo groups on the ring system.  




1,3,6,8-tetrabromopyrene 61 and 3,3',5,5'-tetrabromo-1,1'-biphenyl compounds 62 
(Scheme 14) were chosen to work with the Heck reaction because of favourable steric 
considerations. 
The initial reactions attempted featured the coupling of acrylamide to 1,3,6,8-
tetrabromopyrene 61. For this, Pd(OAc)2 (86.2mg) and  Tri(o-tolyl)-phosphine (115 mg) 
were placed in a Schlenk tube and mixed with DMF (20 ml). Following this, acrylamide (1 
g), 1,3,6,8-tetrabromopyrene (250mg) and triethylamine (2mL) were added. Same as 
previous reactions, the mixture was heated up to 90oC and left for 24 hrs. This reaction did 
not successfully take place, potentially owing to solubility issues. Several other solvents 
were tested in order to enhance the solubility. The choice of the solvents was investigated 
through a small volume solubility testing. 
Table 2 Reaction conditions tested in order to couple acrylamide onto 1,3,6,8-tetrabromopyrene via 
Heck Reaction. 
Conditions Results 
DMF, Pd(OAc)2, tri-(o-tolyl)phosphine,Et3N, 90oC 
 
No reaction 










MeOH No reaction-insoluble 










61 63 61a  
Scheme 14 Heck Reaction was used to couple methyl acrylate to 3,3',5,5'-tetrabromo-1,1'-biphenyl 
61. 
Despite trying numerous solvent systems, we decided to work with 3,3',5,5'-tetrabromo-1,1'-
biphenyl 61 and methyl acrylate 63 which was successfully coupled to four positions 
(Scheme 14). The reaction was completed as shown by TLC monitoring. This structure was 
confirmed by NMR and Mass Spectroscopy to validate successful coupling of all four 
positions. Following to this reaction, we decided to couple amine groups onto these four 







Figure 29 Assigned HSQC (Heteronuclear single quantum coherence spectroscopy) and integrated 
1D-1H spectra for 3,3’,5,5’-tetrabromo-1,1’-biphenly 61 coupled with methyl acrylate. From the 1D 
proton, we see the four protons of the alkenes groups at 6.5ppm (H-a) (integrated as 4) and the other 
one is at 7.7ppm (H-c) integrated as around 4. We also see by this peak there is a peak giving an 
















Figure 30 Assigned NMR spectra and structure representing coupled methyl acrylate 63 to 3,3',5,5'-
tetrabromo-1,1'-biphenyl 61. 
3.4 EDCI.HCl coupling 
 
Since many of the more complex amines would not be well suited for conversion to 
acrylamide and/or coupling via the Heck reaction, it was necessary to consider different 
possible routes to synthesise a library of compounds based on 52 and 53. Whilst, in our 
hands, the acrylamide couplings using palladium catalysts afforded poor yields, the 
corresponding coupling with acrylates, has been shown to proceed to completion with high 
yields. As a result, we used the synthesis of methyl acrylate derivatives of 60c with a view 
to subsequently hydrolysing them for coupling using carbodiimide methods.  
64  
Figure 31 Coupling agent EDCI 64. 
 
 




EDCI is the most common coupling reagent for peptide synthesis and with the addition of 
HOBt it becomes more efficient. Therefore, it was decided to try the first coupling with this 
coupling reagent.   
In the case of the anthracence bis-(carboxylic acid) 60d, 1 eq. of diester and methanol (5ml) 
were stirred and KOH (2 eq.) was added and stirred at 77°C under reflux until the starting 
product was consumed (checked by TLC). HCl (4M) was used to quench the reaction 
mixture and pH was taken down to 2. Hydrolysis was verified by NMR. 
a b
 60d 60c 
 45
 
Scheme 15 Reagents and Conditions: a) Pd(OAc)2/Ph3P/ CH2=CHCOOCH3/DMF,84-95%; b) 
MeOH, 4N NaOH, 92%. 
With the diacrylic acid derivative 60d in hand, facile conversion to the corresponding amide 
could be achieved using diacid (1eq.) and amine group (4eq.) in DCM solution at room 
temperature under N2. To this solution, a mixture EDCI.HCl (4eq.) (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide) and HOBt (Hydroxybenzotriazole) (4eq.) in DCM 
(dichloromethane) solution was added dropwise at 0°C. Then, DIPEA (N,N-
diisopropylethylamine)  (8 eq.) was added dropwise to the solution mixture and was left to 
stir (221). This afforded the amides referred to as type 52 (Figure 22) 
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50%  
Scheme 16 Synthetic routes for EDCI coupling,50% yield. 
 
EDCI coupling reagent was used to couple chosen amine groups onto 60d. With the 
reaction scheme shown in Scheme 16, we successfully coupled two compounds (52a-52c) 
(full synthetic routes shown in Scheme 17)). Alongside these two successfully coupled 
compounds, it was found that two other amine groups were unsuccessful as shown in Table 
3. This failure to couple was explained by the amine groups insolubility in the reaction 
solution of DCM or DMF. Despite numerous reaction conditions being tested to solubilise 
these amine groups (b and f) (Figure 24), including experiment time, temperature, and 
solvent choice (THF, MeOH), there was still no successful coupling seen.  52a and 52c 
were successfully coupled at yields of 55% and 41% respectively. This lower than expected 
yield can be explained by the reaction mechanism where mono amide coupling has to 
happen first before generating diamide coupled compound. This means that we can lose 
higher yields through the isolation of mono substituted amide compound. 
 
















 Scheme 17 Synthetic route for 4-(aminomethyl)pyridine via EDCI coupling. 
Table 3 Comparison of yields, experiment times and structures of specific EDCI coupled amine 
groups to anthracene core. 
 
Amine group (see 
Table 1) 




24 h 55% 
b 
52b  




24 h 41% 
f 
52f  
12 h No reaction - 
insoluble 




3.5 Acrylamides based on 1,3,5-trisubstituted phenylbenzene 
 
Our first example is 1,3,5-tris(4-bromophenyl)benzene 66 which will permit coupling with 
three amine groups. We prepared 1,3,5-tris(4-bromophenyl)benzene 66 coupled with 
methyl acrylate via Heck reaction in preparation for 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) coupling with selected amine groups to form a 
library of derivatives. We optimised the yield of this product to be hydrolysed for EDCI 
coupling.  We found that reducing the quantity of catalyst activating ligand allowed for easier 
purification of the product. This led to decreased decomposition/loss of product and 
increased yield. Other steps taken included varying reagent concentration and the relative 
molar equivalency of reactants.  
Figure 32 Assigned 1D-1H spectra for 1,3,5-tris(4-bromophenyl)benzene coupled with methyl 
acrylate. From the 1D proton, it shows that three alkene groups at 6.7ppm (H-e), 7.8ppm (H-d) as 
integrated 3H. The biphenyl appears at 8.05ppm (H-a), 7.96 ppm (H-b) and 7.85 (H-c). Therefore, 
the corresponding integrals match those of expected. 
Heck Reaction of 1,3,5-tris(4-bromophenyl)benzene 66 and methyl acrylate provided a  
product of 1,3,5-trisalkyl substituted phenylbenzene derivative. After producing good yields 
of the ester compound, it was decided to convert it to the trisacid 67a. We investigated ways 
to enhance the efficiency of coupling through the use of tandem reactions which judge the 




applicability of each reaction to this coupling. The reported effectiveness of couplings 
allowed us to select agents for this investigation. This procedure was followed by coupling 
amine groups onto the trisacid compound using EDCI.HCl and HATU couplings.  
EDCI.HCl was used to couple benzylamine to the trisacid 67a. A solution of EDCI and HOBt 
were pre-prepared in DMF (7.5ml) and then it was added drop wise to a stirred mixture of 
trisacid and a couple of benzylamine. Then to this mixture 0.2ml of DIPEA was added. 
These conditions were carried out under N2. This experiment was done to evaluate whether 
small amine couplings gave efficient coupling through EDCI coupling at two positions. 
However, through NMR results we saw that only one position coupled. There were also 
mixtures of derivatives which were apparent in the spectra. Due to the complexity of the 
spectra, it was decided that the EDCI coupling produced a number of derivatives and as 
such that a (1-[Bis(dimethylamino)methylene]1H-1,2,3-triazolo[4,5-b]pyridinium3-oxide 
hexafluorophosphate (HATU) coupling would be attempted to selectively produce desired 
product.  
HATU 68 has been shown in previous literature to have greater coupling effectiveness when 
compared to HOBt within solid-phase peptide synthesis. This synthesis was done with 
sterically hindered amino acids which was relevant to our couplings (222). 




1. primary tautomerism and 
activation of amino acid
2.Nucleofilic attack of HOAt anion to newly 
activated carboxylic acid
3.The amine reacts with the activated 
ester to form the amide, this reaction 
is oriented by the coordination shown 
by dashed line.  
Scheme 18 Mechanism of HATU 68 peptide coupling.  
 
For HATU coupling, the trisacid 67a compound, benzylamine, HATU and DIPEA were 
added with DCM as a solvent. This mixture was stirred at room temperature for 20hrs. 
During the reaction period, TLC was used to monitor the reaction. TLC showed that product 
was being made at very low concentrations, therefore, temperature was raised to improve 
the kinetics of the reaction. Subsequent work up of the reaction showed that negligible 
product was produced. This may have been because of energetically unfavourable 
conditions leading to only one coupling side in the reaction.  
To gain an aldehyde functional group which would make coupling of amine groups more 
accessible. We decided to attempt reduction of diacid with DIBAL. After several 
unsuccessful reactions with diethylacetal and DIBAL which resulted in the reduction of the 
starting material to an alcohol, it was decided to then address this issue with imine couplings 
to bypass issues common to previous reactions.  











Figure 33 Illustration representing the desired and obtained compound using DIBAL with yield 
included. 
 
Alongside the DIBAL reduction of diacid 60d and peptide coupling using HATU of trisacid 
(67a), we attempted to couple acrylamide to 1,3,5-tris(4-bromophenyl) benzene via Heck 
Reaction. To do this, Pd(OAc)2 and  DPPP (1,3-Bis(diphenylphosphino)propane) was 
added to DMF and  stirred under nitrogen conditions. To this mixture, triethylamine and 
acrylamide were added. Reaction was heated at 90oC for 24hrs. TLC was used to monitor 
the reaction. When one new spot was left the reaction was stopped. NMR analysis 
confirmed the proposed product had been synthesised. To confirm the molecular weight 
and atomic structure, mass spectrometry was used to validate the NMR results. From the 
NMR and mass spectrometry, we saw no impurities, so column chromatography was not 
needed in this case. 








Scheme 19 Heck coupling based on 53 (20%yield). 
 
 
3.6 Imine couplings 
 
After experiencing difficulties with EDCI, HATU and DIBAL reactions we decided to carry 
on our research by synthesising imines. Our intention was to couple bulky amine groups to 
the anthracene-9,10-dicarbaldehdye 72. The coupling of these bulky amine groups to the 
anthracene-9,10-dicarbaldehyde follows the reaction mechanism of a Schiff base reaction 
where an ammonia molecule or primary amine will attack a carbonyl group. We also see a 
similarity in the formation of an acetal, as when water is eliminated in the acid catalysed 
reaction, we see a reversible reaction, much like the acetal. Because of this the pH of 
reactions must be carefully controlled to give the greatest yield of final imine compounds 
without allowing the equilibrium to return to starting material. It has been shown that for 
these reactions a pH near 5 gives the greatest rate of equilibrium to the imine product and 
drops at higher or lower pH for kinetic and electrophilic reasons. This is because at high pH 
there is less acid to protonate the OH in the Schiff base intermediate and dehydration of 
H2O will not occur. Conversely, at low pH the amine reactant will be mainly present as an 
ammonium conjugate acid and unable to take part in the reaction as it will no longer be 
nucleophilic.  








Scheme 20 An example of an imine coupling scheme using 3-morpholinopropan-1-amine m to 





Scheme 21 Synthesis of imine derivative 55m from 72. 
The reversible nature of the imine reaction facilitates the establishment of a dynamic 
combinatorial approach to this class. This would enable the in-situ amplification of a specific 
di-imine from our anthracene derivative depending on the thermodynamics associated with 
exposure to quadruplex over duplex DNA. 
Whilst it was intended that we would combine multiple amines in the presence of a G-
quadruplex-forming oligonucleotide, to ascertain amplification of one or more imine 




products, we ultimately formed and tested a small static combinatorial library for anti-cancer 
activity. 
DCM, reflux at 50 oC
 5572  
Scheme 22 Synthetic route used to form imine derivatives from 72. 
Reaction of a series of amines a, c, j-m to 72 was achieved using 2.3 equivalents of amine 
in DCM and heated to 60oC. This reaction was performed under N2 atmosphere for 24hrs. 
Reaction was monitored by TLC with (1:1) EtOAc+Hexane solvent system until a steady 
state was achieved after 24 hrs. TLC monitoring showed that no starting material was 
persisted. Therefore, the resultant product was precipitated and then the solid was 
recrystallised using MeOH. The yield was 78% which alongside melting point and NMR 
analysis of impurities being negligible, the reaction was not further optimised.  
After the successful coupling of piperolamine (yield 78%), reaction of 3-
morpholinoprorylamine and 2-amino-5-methylthiazole with 72 was undertaken. The same 
reaction procedure was used to achieve the expected compounds.  The expected 
compounds were synthesised smoothly with yields of 60% and 75% respectively. These 
successful results urged us to couple adenine as we previously had difficulties to couple 
this compound using EDCI.HCl couplings. Adenine is a nucleotide, the structure itself 
includes amino protons which present positive charges to bind to O- in the phosphate 
backbone of the G-quadruplex structures. However, using the same reaction conditions, 
due to the solubility issues of the adenine, the coupling reaction with 72 did not occur. 
Resolution of these issues through changing the solvent system such as dry toluene and 
dry DMF. In both cases, adenine was still present in the reaction. This was monitored by 
TLC (1:1) EtoAc+Hexane and 10%Methanol+DCM solvent systems respectively for 48 hrs, 
but without evidence of any reaction. 




Following this success, tryptamine, (1-,2-aminoethyl) piperidine and 3-aminoacetanilide 
were reacted under the same conditions to the carbaldehyde in 80%,45% and 35% yields 
respectively. Tryptamine is a known monoamino alkaloid which was selected based upon 
its amino group position in the ring system. A piperidine compound was also chosen as it’s 
a starting material in the synthesis of anticancer analogues. It was also hoped that 3-
aminoacetanilide would afford a well-placed hydrogen bond acceptor/donor configuration 
to aid backbone binding to the G-quadruplex.  
Having successfully coupled several amine groups onto the carbaldehyde, it was decided 
to introduce 2-aminothiazole-5-carbonitrile a, in cancer research, thiazole derivates have 
had a huge impact, demonstrated through the reported inhibition of proliferation and growth 
of cancer cells alongside reducing the ability for neovascularization. These properties are 
seen through several different modes of action in a diverse range of therapeutic targets.   
This reaction of 1 equivalent of carbaldehyde and 2.3 equivalent of 2-aminothiazole-5-
carbonitrile were first performed in DCM and stirred at 40OC. The reaction mixture was then 
left for 24 hrs. TLC was used to monitor the reaction. However, on the TLC comparing 
resultant to starting material, there were 4 spots appearing for the resultant compared to 
the one spot for the starting material. The starting compound was still strongly apparent. 
We wanted to further investigate the resultant using NMR. The NMR showed a mixture of 
compounds with several aromatic environments. This demonstrated that the reaction did 
not go to completion and the desired product was not formed. This led us to work with other 








Table 4 Comparison of yields, experiment times and structures of specific imine coupled amine 
groups to anthracene core. 
Amine 
group 
Target compound time(hours) Isolated yield 
a 
55a  
24 h 78% 
m 
55m  




12 h 80% 
c 
55c  
24 h 65% 
j 
55j  
24 h 75% 
l 
55l  
24 h 35% 
 





Figure 24 1H-NMR spectrum and proton assignments of N-[3-[(E)-[10-[(E)-(3-
acetamidophenyl)iminomethyl]-9 anthryl]methyleneamino]phenyl]acetamide 55l. 
 
Before the cell culture work, we decided to test one of the imines synthesised for stability in 
Dulbecco’s Modified Eagle’s Medium (DMEM). This work would show if the imine coupled 
compounds were stabile for the incubation period of treatments and hydrolysis was kept to 
negligible levels. This was achieved by preparation of the compound concerned in cell 
culture (DMEM) modal system and monitored via NMR. Using an internal standard (TSP), 
we could quantify compound peaks at time 0 and time 24 to see if hydrolysis of the imine 
group had occurred.  
 





Figure 35 Top NMR spectra represents aromatic and imine peaks for compound 55j after 24 hours 
incubation in modal cell culture system (DMEM) at 37oC. Bottom NMR spectra represents aromatic 
and imine peaks for compound 55j at time 0 in model cell culture system (DMEM). Both spectra are 
matched to internal standard integrals. 
We see from Figure 35 that after 24 hours there is a small drop in peak height but no new 
peaks forming which suggests that minimal to no hydrolysis has occurred. This gives 
confidence in the stability of our imine coupled compounds when incubated up to 24 hours 
at 37oC. This was tested to see if the imine bond formed through the coupling is hydrolysed 
in the water environment. Only one compound was tested as the imine bond for imine 











3.7 Cell culture results 
 
It was decided to test synthesised compounds on cervical cancer cell lines (HeLa, American 
Type Culture Collection (ATCC) (ATCC® CCL-2™). For the testing Presto Blue Assay gave 
the most significant results when compared to MTT and Neutral Red Assay as these two 
assays were interacting with the compounds when they were treating the cells with the 
medium. With the neutral red assay, the eurhodin dye during the 24-hour preparation time 
can precipitate into fine crystals which can become visible and interfere with absorbance 
readings. This is very difficult to reverse and account for, so induction of precipitation by 
slightly different conditions can give inconsistent results. Alongside this limitation, the assay 
is (Neutral red assay) very expensive and is more time consuming than alternatives. With 
both MTT and Neutral red assay the absorbance levels were inconsistent with many outliers 
that prevented repeatability measurements. MTT was first shown to interact with the drug, 
reducing tetrazolium to formazan rather than the cells exclusively carrying out the reduction. 
Presto Blue was selected because after preliminary testing no anomalous results were 
seen. Since the presto blue assay functions through the reduction of resazurin to the 
florescent resorufin, the issue of precipitation is bypassed and alongside this the incubation 
time is a lot smaller and less time consuming (Presto blue= 30 mins, MTT and Neutral red 
assay= 1 to 4 hours).  This smaller incubation time could be a factor in the reduced effect 
of drug reduction when compared to the MTT assay despite aspiration of compound there 
could be drug compound remaining which overtime would give larger discrepancies. 
Presto Blue Assay was prepared as per protocol (223). It was added in 200µL per well, all 
prepared well plates were then incubated for 1 hour. After the incubation time, plates were 
read at both 570nm absorbance and 600nm reference wavelength with absorbance being 
proportional to the viability of cells. Linear detection of cells down to 98 cells per well with a 
Z value of greater than 0.5. This Z factor means that negative and positive controls will have 
a large separation band. DMSO and Doxorubicin were used as negative and positive 
controls throughout the Presto Blue assay. 9µL of Doxorubicin stock 1% solution (40mg in 
4ml DMSO) was prepared in 9ml of DMEM stock solution to make a 10µg/ml solution and 




added in 200µL to wells, and DMSO was prepared in 0.1% solution in DMEM (3µl to 3ml 
DMEM), then added to cells in 200µL.      
All novel compounds were tested against a HeLa cancer cell line (HeLa, American Type 
Culture Collection (ATCC) (ATCC® CCL-2™) and they were all prepared in 100,30,10 and 
1 µM concentrations so that IC50 values could be calculated to establish whether drugs were 
cytotoxic to HeLa cells.  
Preliminary experiments were done to screen for activity and synthesised compounds that 
showed activity were run in triplicate to get an average, SD and SEM values, 
Figure 36 Bar chart showing the normalized cell viability of HeLa cells for concentrations 100...1µM 
of non-inhibiting compounds; 52a, 52c, 53a. Showing non-significant inhibition of HeLa cells. 
Following the preliminary experiments 3 compounds were excluded from further testing; 
52a, 52c and 53a. Compounds; 55a, 55m, 55j, 55k ,55c, 60a, 60b, 60c were progressed 
to triplicate testing and further statistical analysis e.g. IC50 determination, repeatability 
(Mean and standard error of mean).  





Figure 37 The data shown is after 24-hour incubation of drug (55a) treated HeLa cells. Top chart 
illustrates Mean and SEM of HeLa cell viability at concentrations 100 to 1µM with positive control 
(N2). In the top chart, values are normalized to negative control at a value of 1 (cell viability). The 
bottom chart then shows the normalized absorbance percentage to the negative control (percentage 
cell viability) of log inhibitor concentration (multiplied by 10 to account for 1 µM concentration) IC50 










Figure 38 The data shown is after 24-hour incubation of drug (55m) treated HeLa cells. Top chart 
illustrates Mean and SEM of HeLa cell viability at concentrations 100 to 1µM with positive control 
(N2). In the top chart, values are normalized to negative control at a value of 1 (cell viability). The 
bottom chart then shows the normalized absorbance percentage to the negative control (percentage 
cell viability) of log inhibitor concentration (multiplied by 10 to account for 1 µM concentration) IC50 
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Figure 39 The data shown is after 24-hour incubation of drug (55j) treated HeLa cells. Top chart 
illustrates Mean and SEM of HeLa cell viability at concentrations 100 to 1µM with positive control 
(N2). In the top chart, values are normalized to negative control at a value of 1 (cell viability). The 
bottom chart then shows the normalized absorbance percentage to the negative control (percentage 
cell viability) of log inhibitor concentration (multiplied by 10 to account for 1 µM concentration) IC50 












Figure 40 The data shown is after 24-hour incubation of drug (55k) treated HeLa cells. Top chart 
illustrates Mean and SEM of HeLa cell viability at concentrations 100 to 1µM with positive control 
(N2). In the top chart, values are normalized to negative control at a value of 1 (cell viability). The 
bottom chart then shows the normalized absorbance percentage to the negative control (percentage 
cell viability) of log inhibitor concentration (multiplied by 10 to account for 1 µM concentration) IC50 











Figure 41 The data shown is after 24-hour incubation of drug (55c) treated HeLa cells. Top chart 
illustrates Mean and SEM of HeLa cell viability at concentrations 100 to 1µM with positive control 
(N2). In the top chart, values are normalized to negative control at a value of 1 (cell viability). The 
bottom chart then shows the normalized absorbance percentage to the negative control (percentage 
cell viability) of log inhibitor concentration (multiplied by 10 to account for 1 µM concentration) IC50 











Figure 42 The data shown is after 24-hour incubation of drug (60c) treated HeLa cells. Top chart 
illustrates Mean and SEM of HeLa cell viability at concentrations 100 to 1µM with positive control 
(N2). In the top chart, values are normalized to negative control at a value of 1 (cell viability). The 
bottom chart then shows the normalized absorbance percentage to the negative control (percentage 
cell viability) of log inhibitor concentration (multiplied by 10 to account for 1 µM concentration) IC50 










Figure 43 The data shown is after 24-hour incubation of drug (60a) treated HeLa cells. Top chart 
illustrates Mean and SEM of HeLa cell viability at concentrations 100 to 1µM with positive control 
(N2). In the top chart, values are normalized to negative control at a value of 1 (cell viability). The 
bottom chart then shows the normalized absorbance percentage to the negative control (percentage 
cell viability) of log inhibitor concentration (multiplied by 10 to account for 1 µM concentration) IC50 












Figure 44 The data shown is after 24-hour incubation of drug (60b) treated HeLa cells. Top chart 
illustrates Mean and SEM of HeLa cell viability at concentrations 100 to 1µM with positive control 
(N2). In the top chart, values are normalized to negative control at a value of 1 (cell viability). The 
bottom chart then shows the normalized absorbance percentage to the negative control (percentage 
cell viability) of log inhibitor concentration (multiplied by 10 to account for 1 µM concentration) IC50 











3.8 Intercalation G4 results 
 
With doxorubicin being used as the positive control in the HeLa cancer cell lines cytoxicity 
studies, which has been shown to intercalate with G-quadruplex structures, (204) our 
studies investigated the intercalation of synthesised cytotoxic compounds with the same G-
quadruplex model structure used d(TTGGGTT)4. Comparing intercalation of the 
doxorubicin derivative nemorubicin with d(TTGGGTT)4 and our novel compounds. It has 
been shown that the motif present in telomeres that forms their G-quadruplex structures is 
(TTAGGG)n. With this knowledge, it was decided to select an oligomer that had three 
guanine residues. TTGGGTT was decided upon because of its symmetry, which allows for 
easier assignment of peaks. It was selected as a 7 base oligomer rather than a larger 
oligomer with multiple 3xG sites, as it is known that tetramer g-quadruplex’s will always be 
in the parallel configuration. This gives a cleaner NMR spectrum to profile the interaction 
between G-quadruplex and drug compound. Despite there being an increased stabilisation 
for oligomers that have an adenine residue at position 2, instead of thymine through the 
formation of an adenine tetrad, it has been shown to give a 2:1 intercalation stoichiometry 
for doxorubicin in between A2 - G3 and G5 – T6. This intercalation at A2 – G3 was seen as 
not necessary for this screening and would make screening more complicated. This idea is 
supported by previous screening studies that have focussed on the intercalation at position 
G5-T6, which forms a cap on the complex. Previous literature with 
d(T(1)T(2)G(3)G(4)G(5)T(6)T(7))4 (numbers in parenthesis added for reference) has 
demonstrated that G-quadruplex ligands intercalate specifically at the point between G5-T6 
(204) . Large broadening of G5 imino proton peaks, accompanied with an up-field shift, 
shows this. We also see the peaks for T6 (methyl, aromatic and ribose) shifting to a lower 
field in accord with the up-field shift of the G5 peaks. This change is explained by the 
formation of a complex between the ligand and the tetrad formed at G5, which pushes the 
T6 unit away from the guanine π –system. This intercalation framework was in agreement 
with ESI/MS carried out which illustrated a 1:1 complex (204).  
 




The comparative intercalation analysis of active compounds was achieved through NMR 
titration experiments, where differences in peaks were investigated primarily at the guanine 
imino protons at 10-12ppm and the number 6 thymine (T6) protons, which are at the 
proposed site of ligand stacking next to the guanine residues which form the G-tetrads. To 
validate the formation of G-quadplexes, imino peaks at 10-12ppm are first detected. The 
number of imino peaks at 10-12ppm in an exchanging D2O environment represents the 
number of quartets that would make up the G-quadruplex. We see from Figure 45 that there 
are three guanine tetrads formed with peaks at 11.55, 11.22 and 10.86ppm respectively 
(224).  
 
Figure 45 Imino peaks indicative of G-tetrad formation labelled with guanine number in aptamer 
d(TTGGGTT)4. 
We see in Figure 46, much like the work done by (225), that line broadening and up-field 
shift occurs at peaks representative of proton G6NH (10.79ppm) significantly, alongside the 
significant peak broadening and down field shifting of T6H6/8 and T6CH3 peaks with the 
addition of proposed ligands. These significant changes demonstrate distinctly different 
bound and unbound forms through large broadening effects at a ratio of 0.5:1. There is also 
subtle line broadening and up-field shifting of G4NH (11.48ppm) and G5NH (11.15ppm) for 
each ligand that shows chemical exchange between two similar environments of bound and 
unbound. Maximum line broadening occurs at a ratio of 1:1 drug to G-quadruplex and 
chemical shift difference changing up to 1:1 with the bound and unbound peaks being 




present. This matches the effect seen by nemorubicin intercalation with d(TTGGGTT)4 in 






























Figure 46 1D 1HNMR Spectra, referenced to TSP, showing titration of drug compounds and d(TTAGGGT)4. A slow exchange interaction, is illustrated with black arrows 
and fast exchanging interactions by blue arrows 




In Figure 46 we see the drug compounds that display Drug-quadruplex interactions that 
match the effects of nemorubicin on the chemical shifts of d(TTGGGTT)4. In reference to 
the chemical shift differences values seen for nemorubicin: T6CH3 = +0.24; T6H6/8 = 
+0.34; G3NH = -0.11; G4NH = -0.15; G5NH = -0.36, which are taken as strongly 
intercalating values, with 2D NOESY results highlighting strong through space interactions. 
These values illustrate relative targets for chemical shift difference, which are suggested to 
elicit greater effectiveness and improvements in IC50 values with greater interaction seen 
between quadruplex structure and ligand.  With ppm differences highlighted for the G3, G4 
and G5 imino protons and T6 thymine peaks in Table 5 for each drug, we can then group 
the effects on G-quadruplex environment by different coupled groups and calculated IC50 
values shown in Figure 47 to determine if the suggested relationship is feasible.  
Table 5 Measured at 27°C in ppm (δ) and referenced from internal standard TSP. Solvent H2O- 

























55a 0.09 0.17 -0.04 -0.08 -0.2 
55m 0.093 0.22 -0.066 -0.135 -0.34 
55j 0.146 0.19 -0.056 -0.11 -0.24 
55k 0.157 0.126 -0.06 -0.115 -0.25 
55c 0.094 0.16 -0.03 -0.07 -0.13 












Figure 47 NMR Spectra referenced to TSP, showing titration of compounds that showed no interaction between drug and G4 
 
 




In Figure 47 we see the compounds that do not show intercalation to the G-quadruplex, 
with control compound 53a (no HeLa cell inhibition), HeLa cell inhibitors 60c, 60b and 60a 
which we propose inhibit cell growth activity through a non-intercalating method of action.  
The compounds that show intercalation see significant differences for several of the 
compounds that we can rank alongside the IC50 values of compounds to give a rudimentary 
correlation between IC50 values shown in Figure 48. We see two groups of correlating IC50 
and chemical shift differences appearing with similar linear correlations of y=44.423x + 
9.4167 (r2 = 0.9864) and y=56.333x + 16.517, with one group of compounds containing 




Figure 48 IC50 versus chemical shift differences in the G5NH peak of intercalating compounds with 











Chapter 4 – Discussion




The initial aim was to build a library of acrylamide compounds to couple to 9,10- 
dibromoanthracene 45, as demonstrated previously by Le Gresley et al. (193) that through 
the use of Heck methodology, acrylamide couplings could be done after an initial reaction 
between acryloyl chloride and chosen amine groups. Anthracene was selected as our first 
structure to be investigated because of its favourable properties as a possible G-quadruplex 
intercalator alongside its demonstratable ease of use in synthesis. Working with anthracene 
for synthetic work is made easier by the solubility of anthracene in multiple solvent systems 
therefore allowing for multiple reaction schemes to be attempted. Another aspect that 
makes it favourable for this work was its relative inexpensiveness and reactivity, which 
meant that longer experiments are reduced.  
Generation of acrylamides for coupling to 9,10-dibromoanthracene was done in a view to 
build upon previous libraries and investigate these coupled products for their intercalation 
potential and also ability for further modification to create novel G-quadruplex ligands with 
greater affinity.  
 One of the first amines we worked with was piperonylamine (59a) because it has the 
benzodixol ring, which could promote intercalation with G-quadruplex DNA. We decided to 
synthesise different types of acrylamides such as 4-(aminomethyl)pyridine and adenine. 
However, due to difficulties in separating these products from the reaction mixtures, we 
chose not to pursue synthesis of the acrylamides. The rationale for ceasing synthesis of 
these acrylamides was that acryloyl chloride substitution was not successful. It is thought 
the reason for this is that the nitrogen present on the rings of several chosen amine groups 
interfered with the coupling of acryloyl chloride to the primary amine targeted in this 
coupling. This hypothesise is supported by the large mixtures of products present after 
reaction. Despite these difficulties, we carried on using the amine groups in EDCI.HCl 
coupling and imine couplings.   
Working with nucleotides was also problematic, especially with adenine and guanine, as 
they are difficult to solubilise in organic solvents. Multiple solvents systems were tried, for 




example DMF, acetonitrile and chloroform. However, despite many attempts, none of them 
gave verifiable acrylamides. This suggests that nucleotides, which are interesting amines 
to investigate as previously stated, aggregate by intermolecular interactions between 
individual molecules. This interaction, alongside preventing solubility in most solvent 
systems, could also bring about issues in single nucleotide coupling to acryloyl chloride. 
Imidazo[1,2-a]pyridin-3-amine, 7-methyl-2-phenyl-(h) was one of the other amine groups 
selected due to the presence of two tertiary amines in the structure. Despite being a primary 
amine, which was thought to readily couple to our acid chloride, the amide was not formed. 
It was suggested this was because of the large side structure of the primary amine and 
possible transfer of free electrons away from the primary amine group to the large electron 
dense side chain of imidazo[1,2-a]pyridine group. In this situation, solubility of amines was 
also a limiting factor. There is previous evidence showing why nucleotides have poor 
solubility, which suggests that a similar mechanism may be preventing solubility of other 
type of amines that contains secondary or tertiary amine groups.  
Afterwards, it was decided to couple piperonylamine acrylamide (59a) to 9,10-
dibromoanthracene using the Heck Reaction. The solvent system used was dry DMF, as 
previous literature showed that this gave the highest yield when compared to other common 
solvent systems (226). It is thought this is because DMF demonstrates improved dispersion 
and reduced aggregation of catalyst during reaction (227).  During the reaction, the mixture 
precipitated a black solid. Analysis of solid by NMR and TLC showed a mixture of the 
starting material and partial coupling to the anthracene ring. For this reaction, several types 
of palladium catalyst and ligands were tested, shown in Table 6.  








Pd(OAc)2 Tri-(-o-tolyl)phosphine 60a,60b 
Pd(OAc)2 Triphenylphonsphane 61a,60c 




However, in our hands, none of them achieved successful Heck coupling. It is thought that 
the complexation of the palladium catalyst by nucleophilic groups distal to the acrylamide 
lead to a deactivation of catalyst. Another intriguing finding was that piperonylamine in its 
amine form not its acrylamide form was able to couple with modified anthracene ring to form 
(60d). This illustrates that the anthracene ring was either too active when not modified for 
this reaction and the conditions that might have been required or the piperonylamine 
acrylamide was not reactive enough. Bond-energy calculations could be interesting to study 
to decide whether this is the case. A suggested reason for unsuccessful coupling was the 
low reactivity of acrylamide in the Heck reaction which is illustrated by the long experimental 
time required for not only the unsuccessful couplings but also the successful ones. The 
reason for this could be that electrons in the acrylamide are held in more stable positions 
than acrylates which show higher activity in the Heck Reaction. Complexation of palladium 
catalyst could also be explained by the amine groups not involved in acrylamide formation 
having through space interactions with palladium (II) acetate. The formation of a stable 
complex formation between a simple amine and palladium (II) acetate has previously been 
detailed where aliphatic amines were shown to coordinate strongly with palladium to form 
a complex with limited C-H activation (228). This effect is highlighted through the mixing of 
palladium salts stoichiometrically with 2 aliphatic amines which coordinate to the 
electrophilic palladium ion and subsequently form a saturated square-planar complex which 
is unreactive to C-H cleavage this mechanism is shown in Figure 49. This finding supports 
our proposal that palladium is complexed out of solution and it would be appropriate to 
protect amine groups with electron withdrawing groups and other directing groups so that 
C-H activation can be achieved (228). 





Figure 49 Palladium (II) acetate complexation with aliphatic primary amines to form stable non C-H 
activating planar complex. 
After these unsuccessful coupling attempts, we proceeded with the modification of our 
anthracene ring with methyl acrylate and subsequent hydrolysis, yielding the carboxylic acid 
for amide condensation reactions. These reactions met with greater success. With EDCI 
coupling, we were able to couple two amine groups (a,c) , however at the same time we 
had unsuccessful peptide coupling using this coupling agent. Repetition of these couplings 
with  HATU coupling agent, which has previously shown  great coupling efficiency and fast 
reaction rates due to stabilising of  the incoming amine through a hydrogen-bonded-7-
membered cyclic transition state were also unsuccessful in complete coupling with only 
partial coupling at one side (229). 
Having successfully coupled some amine groups of interest with EDCI on 9,10-
dibromoanthracene, we decided to work with other pi-pi staking candidates. To begin with, 
1,3,5-tris(4-bromophenyl)benzene was the first trisphenyl structure to be modified. We 
initially attempted coupling using different types of acrylamide such as N-(Butoxymethyl) 
acrylamide, N-(Isobutoxymethyl) acrylamide and piperonylamine acrylamide via Heck 
Reaction. The full coupling of these acrylamides was unsuccessful, due to coupling on one 
side or two sides rather than three sides and obtaining intractable complex mixtures of 
different derivatives, which were resistant to our attempts at purification and significant yield. 
To achieve any yield experiments also had to run for more than 48 hours, with TLC and 
NMR monitoring showing little product. The synthesis of multiple products with no clear end 
product could be explained by the 9,10-dibromoanthracene and tris(4-












































coupling and alkene migration after initial coupling can produce derivatives of desired 
product (230). Despite these unsuccessful couplings, we attempted to demonstrate that 
coupling could work through the use of a simple acrylamide to remove any side chain effects 
in the action of Heck coupling. From previous studies it was shown that potassium 
carbonate (K2CO3) can be used as an effective base to aid the initial reduction from Pd(II) 
to Pd(0) (230). From the results (Table 4), we see that this coupling was successful and 
means that modifications to amine group could be done post coupling if this compound 
showed potential in anticancer activity or intercalation with G-quadruplex structures.  
It is thought that if we could couple methyl acrylate to this trisphenyl planar structure and 
then transform it to tris carboxylic acid it would be the best candidate for subsequent EDCI 
coupling. The Heck methodology originally used was taken from studies done by Zhao et 
al. (231) where they synthesised 4,4’,4’-benzene-1,3,5-tricinnamic acid at 97% yield. 
Instead of using a phosphine ligand they used a phase transfer catalyst 
tetrabutylammonium bromide (TBAB) to improve the yield and make removal of the ligand 
much easier. Through this method, we also decided to try simple acrylamide (53a) coupling 
to trisphenyl planar structure 53. The reaction was successfully completed within 24 hours 
with a yield of 20%. This shows that acrylamide coupling to trisphenyl planar structure is 
possible, however coupling of larger acrylamides has difficulties from several unknown 
sources. Possibly steric hindrance, electronic effect, or a combination of functional groups. 
Further work clarifying reason for this would be beneficial in choosing the best coupling 
mechanism.  
Imine coupling, through condensation of primary amines with a carbonyl (aldehyde/ketone), 
to form the conjugation between the planar core and selected amine group can be done 
through conversion of our planar core to an aldehyde. Aldehydes have been shown to be 
important functional groups for conjugation of compounds e.g the generation of imines 
(Schiff bases) from aldehydes. The use of aldehydes in this way also benefits from the 
reaction kinetics versus other functional groups, such as ketones, which show a slower 
reaction when forming bonds, specifically shown with hydrazones in research done by Leiro 




et al. (232) it was also demonstrated that aldehydes higher lability under acidic conditions 
providing a potential role in pH-responsive drug delivery.  
Due to these advantages, we decided to start reducing our methyl acrylate coupled 
anthracene ester compound to aldehyde using DIBAL reduction. However, due to the 
reactivity of DIBAL, the ester compound was reduced to alcohol rather than desired 
compound. Therefore, to minimise this problem and to see if the actual imine coupling would 
work; we bought the aldehyde version of the anthracene compound. Testing the imine 
couplings showed relative success in comparison to Heck and EDCI couplings. Getting the 
actual aldehyde also gave us more time to synthesise imine coupled products. This step 
proved valuable as several synthesised imines later showed in vitro culture anticancer 
activity and G-quadruplex intercalation. The imine coupling was robust with several different 
and varied amines coupled to the anthracene aldehyde in good yields (~80% for 55k, 78% 
for 55a and 75% for 55j). The amines had different atoms present such as piperonylamine 
with two oxygens in the ring system and nitrogen atoms present in tryptamine, thiazole, 3-
aminoacetanilide and 3-morpholinoprorylamine, which shows that the imine coupling seems 
relatively unperturbed by multiple amine groups.  
It was suspected that the stability of the imines in commonly used biological buffer would 
be too poor when we considered these compounds for cell viability testing. This would be 
through previously mentioned lability of the imine nitrogen when in aqueous/acidic 
conditions, such as pH-5.5 to 7 commonly used in biological buffers e.g. phosphate buffer 
solution. To our surprise the stability of the imine coupled conjugates was shown to be 
sufficient over the time period and medium conditions measured through incubations of 
conjugates in model conditions with NMR analysis used to monitor changes (Figure 46). 
The NMR analysis showed that the imine bond was stable over 24 hours with negligible 
loss of conjugation in the model system.   
After sufficient stability of imine couplings was established, we picked 11 of the potential G-
quadruplex ligands to be tested in cell culture and for biochemical testing in a model G-




quadruplex system. These compounds were selected so that imine groups, coupling 
methodology and planar core type could be compared and conclusions on their 
effectiveness drawn.  
3 out of the 11 compounds showed no anticancer activity as seen in Figure 36, these 
included 1 Heck coupled and EDCI coupled conjugates, including the trisphenyl planar 
acrylamide compound 53a. Cell culture IC50 values were subsequently determined. They 
illustrated that imine coupled conjugates had a much higher anticancer activity than Heck 
coupled compounds. Alongside a greater variability between different amine groups with 
IC50 values ranging from 18 to 30.6µM with Heck coupled conjugates at 34.9-38.3 µM. This 
suggests that imine couplings have greater potential in drug design and as seen from 
intercalation data may have crucial elements required for stabilization of G-quadruplexes 
that Heck coupled conjugates do not. 
In our results we see that 5 of our 9 compounds that demonstrated HeLa cell line cytotoxicity 
activity demonstrated intercalation with the G-quadruplex model d(TTGGGTT)4. The 
compounds that showed intercalation were interestingly all imine coupled products with a 
tertiary amine present one bond away from the planar ring. With compound 53a, where a 
primary amine exists at the terminal end of the side chain, we see no intercalation despite 
their being more opportunity for G-quadruplex hydrogen bonding with a third amine present. 
We also see that 60c which has no amine present has no intercalation but has HeLa Cell 
line cytotoxicity so the method of cell apoptosis must be through a different mechanism than 
G-quadruplex interaction. We also interestingly see that 60b and 60a, which both have the 
same secondary amine position at 4 bonds away from planar centre of the ligand, have 
similar IC50 values to each other and also 60c but again show no intercalation. This suggests 
that these 3 compounds induce HeLa Cell apoptosis/necrosis through the same method. 
These initial findings from the G-quadruplex intercalation study demonstrates a need for 
tertiary amines in anthracene derivatives to give G-tetrad intercalation potential. 




The anthracene derivatives that contain the tertiary amines, 55a, 55m, 55j, 55k and 55c 
are shown to be have different functional groups present in their side chains; 1,3-
benzodioxole, propylmorpholine, 2,5-dimetylthiazole, 3-Methyl indole and piperidine 
respectively, which we suspect act to stabilise the hydrogen bond between the tertiary 
amine and oxygens of phosphate. However, all of these groups have been shown in 
previous studies to demonstrate DNA and G-quadruplex intercalation alongside anti-cancer 
activity. This suggests that each of these groups may have more of an effect on IC50, than 
solely effects on hydrogen bond stabilisation. They may also make other intercalations 
possible through different mechanisms of binding, apart from g-tetrad stacking as described 
in results.  
We see that the two groups which were grouped by their absence of oxygen or sulphur, 
piperidine and 3-Methyl indole show quite divergent differences in ppm between bound and 
unbound forms of the G4 model. These two compounds also have 2 of the higher IC50 
values of the 5 intercalating compounds, 24μM (55c) and 30.5 μM (55k), which shows that 
despite the range in changes of ppm these two compounds are relative outliers. Previous 
studies have demonstrated non-selective binding to DNA and G4 structures where the 
mode of binding to DNA, like our results, showed a 1:1 stoichometry, with gibbs free energy 
calculations showing a spontaneous intercalation suggesting a stabilising, energetically 
favourable reaction (233). It was also shown that using piperidine as a N-propylamino 
attached to carbazoles gave the highest stabilizing ligands in a study. Interestingly however 
they did identify that there was an inverse correlation between G-tetrad stabilization and G4 
DNA selectivity (234).This is very interesting for our results, as it could begin to explain why 
we see that the relationship between the change in ppm does not correlate completely with 
IC50 values, even showing an inverse relationship to what was expected from nemorubicin 
results (204). It could show that G4 ligands intercalate and stabilise very effectively but IC50 
will be increased as G4 ligand is wasted in duplex DNA intercalation and stabilization. This 
could explain why we see piperidine having similar chemical difference effects and 
stabilization effects to other compounds but has a higher IC50. 3-Methyl indole is less 




investigated for this purpose because of its role primarily as an odourant, with extensive 
use in animal studies. There are however genetic studies that show protective mechanisms 
against damage by 3-methyl indole derivatives that can induce apoptosis at low 
concentrations. This was shown in a study by Nichols WK, where they look at 3-methyl 
indole mediated cytotoxicity in human epithelial lung cells, with CYP2F1 over expressed. 
This is relevant to this study as it shows that 3-methyl indole has a structure activity 
relationship which relates to cytotoxicity of genetically impaired cells, which could possibly 
explain anti-cancer activity (235). The anti-cancer activity of indoles has also been shown 
with indole groups in isoxazolo[5′,4′:5,6]pyrido[2,3-b]indoles, which showed significant 
anticancer activity comparable to standard drugs however the mechanism of action and 
structure activity relationship is yet to be investigated (236). 
The three groups that contained oxygen, sulphur and nitrogen, and nitrogen and oxygen, 
1,3-benzodioxole, 2,5-dimethylthiazole and N-propylmorpholine respectively, showed a 
close linear correlation between their ability to stabilise G4 structure and IC50. The oxygen, 
sulphur and nitrogen containing group had also showed the best IC50 values with 1,3-
benzodioxole and 2,5-dimethyl thiazole as the best candidates for further testing as they 
have similar differences in ppm and also the best IC50 values of tested ligands. Further 
synthesis and reinforcement of DNA binding potential of 1,3-benzodioxole has been 
illustrated by a study which showed DNA binding was moderate to mild and suggested that 
cytotoxic effects were through a different mode of action, which supports the selectivity 
argument for 1,3-benzodioxole (237) .This assumption is further supported by the 
demonstration of testing 1,3-benzodioxole as potential telomerase inhibitors. They 
demonstrated through molecular docking that a benzodioxole derivative had potent 
telomerase inhibition alongside potent anticancer activity in human gastric and human 
melanoma cell lines. They illustrated that the docking of their derivative required two 
intermolecular hydrogen bonds, and two benzene rings which form π-cation interactions 
(238). This shows that this group may add additional benefit through telomerase inhibition 
in a different method of action to the one investigated here with G4 stabilisation, leading to 




telomerase inhibition. The 2,5-dimethylthiazole has been studied a lot in the form of the 
fluorescent marker thiazole orange for its intercalation potential. It was shown in early 
research that thiazole orange binds both as a monomer and dimer to DNA with monomers 
of thiazole orange stacking between DNA bases. It is also shown as the main way of binding 
with duplex DNA. Interestingly they also reported binding to poly(dG) which showed binding 
as a monomer and dimer as well. This supports our results showing intercalation and 
stabilisation of G4  (239). Selective stabilization of G4 structures by thiazole has further 
been supported more recently with studies that showed 1:1 stoichometry between dye and 
G-tetrads in quadruplex DNA. It also illustrated that there was a tight complex formed 
between the two. Interestingly they showed that in the presence of K+ ions, this binding 
seemed to disappear (240). 
Compound 55m, which has a propylmorpholine group has been implemented in the design 
of compounds for telomeric and oncogenic G-quadruplex affinity with varying degrees of 
success. It was shown through molecular docking analysis that compounds made with 
propylmorpholine interact with the groove and or loop of the G-quadruplex, which supports 
our stacking hypothesis through interaction with these external components. This study also 
showed inhibition in the growth of A549 cancer cell lines with low cytotoxicity to normal cells. 
This study concluded that addition of propylmorpholine to naphthalimide supports tumor cell 
cytoxicity selectivity (234)(241). 
With these 5 compounds identified through titration NMR to demonstrate similar binding 
characteristics to previously tested potential anti-cancer drug compound further validation 
of the method of action of these compounds, selectivity, and biochemical methodologies 
etc needs to be done. TRAP assays would potentially be useful and allow for greater 
modification and potentially provide better IC50 values. This would give great insight for 
medicinal chemists who can use these compounds as scaffolds for further investigation. 
The use of NMR for through space characterisation experiments, such as NOESY and 
ROESY alongside molecular docking and interaction studies, STD and tr-NOESY would 
give a clear understanding of the method of action of each of these compounds. 





Table 7 Table comparing IC50 and chemical shift difference between intercalated and non-






Looking at Table 7, we see the IC50’s of doxorubicin and nemorubicin are much lower than 
the IC50 values of our synthesised compounds, however we do see that their Δδ is 
comparable to our two lowest IC50 compounds. This suggests a similar interaction 
mechanism where a 1:1 stoichiometry, with planar stacking on the G6 tetrad, demonstrated 
by the paper where these values were taken from (204). This however does show that G-
quadruplex binding may start through this stacking and be an initiating step for cytoxicity, 
but we see from these results that side chains which give comparable chemical shift 
differences and intercalation stoichiometry produce very different IC50 values. This however 
could be explained by selectivity measures that further studies could elucidate through 
incubation of drug solutions with healthy cells alongside the aforementioned TERT assay 
to measure telomerase inhibition and binding studies with duplex DNA to measure 
selectivity for G-quadruplexes.
Compound Δδ (ppm) IC50 
55k 0.25 30.6 
55m 0.34 24.4 
55c 0.13 23.84 
55j 0.24 20.5 
55a 0.2 18 
Doxorubicin (204) 0.31 0.374 
Nemorubicin (204) 0.31 0.08 
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We successfully synthesised and characterised 19 novel compounds, which include 
potential G-quadruplex ligands, G-quadruplex ligand cores and respective ligand 
acrylamides.  
At the beginning of this research, we attempted to optimise the Heck reaction to facilitate 
C-C coupling reactions. We varied ligands, temperature, and reaction time. This 
optimisation afforded three potential novel G-quadruplex ligands. Following this, 
optimisation of EDCI coupling was done to synthesise two potential novel G-quadruplex 
ligands. Finally, imine couplings were optimised to produce six potential novel G-quadruplex 
ligands with reasonable yields (~65.5%).  
Eleven of these compounds were selected to be tested on HeLa cancer cell lines. Before 
testing these novel compounds on cancer cells, stability tests were done. This helped to 
understand their stability in cell culture media. From cell culture results, it was shown that 
three of the ligands had no cancer activity and eight of the ligands showed cancer activity 
with IC50 values ranging from (~18-31µM). Compounds that showed anticancer activity were 
then investigated using NMR titration studies to elucidate whether ligands intercalated and 
stabilised a model G-quadruplex structure. This investigation showed that the five imine 
coupled ligands showed G-quadruplex intercalation with 1-1 stoichiometry matching that of 
current cancer drugs Doxorobucin and Nemorubicin in this model.   
The promotion of quadruplex DNA formation, as observed in solution by NMR, and initial 
biological testing, suggests the class of G-quadruplex ligand based on imine coupled 
ligands possess an anticancer activity. Further investigation in terms of both 
duplex/quadruplex selectivity, bioavailability, molecular modelling, and stabilisation power 
will allow for a greater of understanding of the QSAR that may exist and allow medicinal 
chemists to build upon these structures. 
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5.2 Future Work 
 
To validate the proposed correlation between cell culture analysis and intercalation of G-
quadruplex structures, a TRAP assay (telomeric repeat amplification protocol) can be used 
to measure the telomerase inhibition by respective G-quadruplex ligands. Moreover, to be 
able to use these G-quadruplex ligands for chemotherapy drug targets, we need to quantify 
selectivity for cancer cells. The incubation and viability analysis of healthy cells with our 
drug targets will give us this information. Combinations of these techniques will give a wider 
picture of which ligands are best suited for further investigation and modification as drug 
targets for G-quadruplex targeting drugs in cancer therapies. 
To further modify novel ligands a Dynamic Combinatorial library can be built. This approach 
uses quadruplex-forming-oligonucleotides to selectively facilitate imine formation, 
metathesis, and other reversible reactions, which can occur in aqueous media in 
physiological conditions. 
Analytical techniques, which can be used to formulate a robust, high throughput assay 
include Circular Dichroism Fluorescent assay and Mass spectrometry(242)(243)(244). 
 
Increased intercalation with G-quadruplex will push equilibrium to the right.  
Scheme 23 Idealised reversible reaction of imine couplings with anthracene tetra aldehyde. 
 
For a more selective approach however the use of molecular modelling will allow for site 
specific alterations to the ligand structures to allow for greater intercalation potential and 
interaction between ligand and G-quadruplex structures. 2D NOESY experiments can show 
through space contacts of G-quadruplex structure in solution when in the bound state and 
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when not in the bound state and this will give insight into how the conformation of the ligand 
affects its intercalation potential and inhibitory effect. Saturation transfer difference NMR 
can also qualitatively compare ligand structure proximity to G-quadruplex structure and 
allow for development of lead compounds with conserved key groups identified. NMR 
fragment-based drug discovery has been recognised as a widely applicable screening 
method (245). Lepre has reviewed the construction of a fragment library through 
development of NMR screening and what to do following a screen to improve drug discovery 
based upon the findings of the screens (246). Group Epitope Mapping (GEM) allows for 
quantitative drug-target interaction through providing definitive information regarding ligand 
binding orientation. This methodology was first applied in 2001 with the 120-kDa protein 
lectin Ricinus Communis Agglutinin I (RCA/20) and its binding relationship with saccharide 
ligands. 
Further synthesis using amines selected by similarity to coupled amines with high IC50 
values and intercalation success will allow for more hit compounds to be discovered and 
elucidate more information on side chain preference. Alongside this selection of new amine 
groups protection of side chain amines and amine groups can be done to confirm 
hypothesis that unsuccessful Heck Coupling was due to complexation of amine groups to 
palladium (II) acetate. Another thing that could be done is coupling of simple primary amines 
to make acrylamides and investigate Heck couplings between these. This would allow for 
comparisons between acrylamide side chains and Heck coupling effectiveness, potentially 
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6.1 General Experimental Methods 
 
1H-NMR spectra were acquired with a Brüker AV400 FT-NMR spectrometer equipped with 
a BB-1H/D Z-GRD probe head (broadband multinuclear with autotune) at a probe strength 
of 400MHz and a Bruker AV600 FT-NMR Spectrometer equipped with a PATXI 1H/D-
13C/15N Z-GRD probe at a probe strength of 600MHz. 13C-NMR spectra were acquired with 
probe routing giving 100 MHz using the Brüker AV400 or 125 MHz when using the Brüker 
AV600. All NMR spectra were acquired with high throughput 5mm NMR tubes o/d, No 
Z107374, Brüker BioSpin AG, Switzerland. NMR spectral measurements were acquired 
with samples completely dissolved in deuterated solvents such as: chloroform-d, 
dichloromethane-d2, dimethyl sulfoxide-d6, or methanol-d4. All NMR peak chemical shifts 
are in ppm relative to an internal standard Trimethylsilylpropanoic acid (TSP) at δ = 0.00. 
All coupling constants use the units of Hertz (Hz). Spectral acquisitions were sweep width 
optimised in 1D 1H spectra and optimised parameter sets specific to 2D NMR (HSQC and 
COSY) were used, these included specific setting of relaxation delays, and sensitivity 
improved pulse sequence for HSQC alongside sweep width optimisation to avoid overlap 
of peaks which cause data aliasing. Acquired Free induction decays (FIDs) processed with 
standard Fourier transform NMR with transients averaging to increase S/N. The data was 
automatically processed with the window function, linear prediction, zero-filling, phasing and 
baseline optimisation set within TopSpin 3.5 pl7 (c) 2017 Brüker BioSpin. 
All solvents were dried using molecular sieves. TLC analysis was performed using Fluka 
glass backed silica gel plates or Merck aluminium backed aluminium oxide. Identification of 
spots was achieved at 254 or 365 nm UVR by a UVP UVGL – 58 multiband UV lamp, 
alongside, iodine, KMnO4, vanillin or ninhydrin stains.  
Low resolution mass spectra (LR MS) and High-resolution mass spectra (HR MS) were 
acquired by MEDAC Ltd. This was done in accordance with BS EN ISO 9001:2008 provision 
for microanalysis service. 
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Infra-red analysis was performed using the neat oil or solid powdered sample coated onto 
ATR disc which is analysed with a ThermoScientific Nicolet iS5 FT-IR spectrophotometer. 
Melting points were measured using Gallenkamp melting point apparatus (serial number 
A090007). 
All chemicals were purchased from Sigma-Aldrich or Fisher scientific. Anhydrous reactions 
were performed using dry glassware which was flame dried under vacuum and carried out 
under an inert nitrogen environment. For work-up procedure deionised water was used with 
saturated LiCl and saturated aqueous solutions of NaCl (brine). Evaporation of volatile 


































Piperonylamine acrylamide was synthesised under dry conditions, DCM (75ml) was added 
into a flask and stirred. Trimethylamine (8.23 ml) and piperonylamine (3.40g) were then 
added into the solution. Acryloyl chloride (2.66 ml) was added in a drop wise manner over   
5 minutes, while the reaction was in an ice bath. The reaction mixture was warmed to room 
temperature and stirred for 1 hour. TLC and NMR were used to monitor and characterise 
the reaction mixture. The resulted crude product was quenched with iced water (200 ml) 
and the organic fraction was separated with DCM (3x50 ml). The organic extracts were then 
washed with acid (3 x 40 ml, 3 M), water (2x 50 ml), NaOH (3x 30 ml, 2 M) and once again 
with water (2x50 ml). The organic component was dried (Na2SO4), filtered and evaporated 
under a reduced pressure. Recrystallization with hot methanol was used to afford yellow 
powder 59a (2.35g, 50.6%). 
1H NMR (400 MHz; d6-DMSO) δ= 4.25 (2H, d, J = 5.90 Hz, CH-1), 5.6 (1H, dd, J = 10.29, 
2.16 Hz, CH-2), 5.98 (2H, s, CH-3), 6.12 (1H, dd, J = 17.12, 2.20 Hz, CH-4), 6.26(1H, 
dd, J = 18.19, 10.20 Hz, CH-5), 6.74 (1H, dd, J = 8.01, 1.58 Hz, CH-7),6.82(1H, d, J= 
1.64Hz, CH-6), 6.84 (1H, d, J = 7.84 CH-8), 8.48 (1H,s,NH) 
 13C-NMR (400 MHz; d6-DMSO) δ= 40.688, 101.299, 107.964, 109.063, 147.72, 125.879, 
126.933, 131.613, 132.628, 146.544, 165.6 
IR (ATR): v= 2971.79, 2864.31, 1649.93, 1248.41, 1054.43 
HR MS (ES) m/z = found 204.0660, requires 204.2029 [M-H]+ 
MP=111-113oC 






Palladium acetate (14mg, 0.25mmol) and 1,3-bis(diphenylphosphino)propane (80mg, 
0.75mmol) were added to a Schlenk tube in DMF (10ml) and stirred at room temperature 
for 10 minutes to generate the active catalyst. After this, trimethylamine (0.6ml) and 1,3,5-
tris(4-bromophenyl) benzene (0.7g) were then added to the reaction mixture, at room 
temperature, followed by addition of 0.3g acrylamide. The mixture was heated at 90°C for 
48hrs under nitrogen. The reaction was allowed to cool and dilute HCl (15 ml, 2M) was 
added. The resulting precipitate was filtered and washed with water (3x 20 ml) and diethyl 
ether (3x15 ml) and dried under vacuum to afford 53a as a white solid yield: (0.49g,74%). 
1H NMR (400 MHz; d6-DMSO) δ= 8.01 (3H, s, CH-2), 7.99-7.94(6H, 7.97 (ddd, J=8.28, 4.12 
,  2.12 Hz, CH-1), 7.97(d, J=16.02 Hz, CH-4), 7.74-7.68 (6H, 7.71 (ddd, J=8.51, 8.41,  1.71, 
CH-3), 6.7(3H ,d, J=15.86 Hz, CH-5) 
13C-NMR (400 MHz; d6-DMSO) δ= 122.424, 125.483, 127.624, 128.684, 134.876, 138.626, 
141.226, 141.416, 167.165 
IR (ATR): v= 3706.08, 3679.45, 2980.20, 2921.54, 1658.28, 1591.5. 

















Palladium acetate (119mg, 0.534mmol) and tri-(o-tolyl)phosphine (162.5mg, 0.534mmol)  
were added to a Schlenk tube, followed by stirring in DMF (10ml) for 10 minutes at room 
temperature to generate the catalyst. After activating the catalyst trimethylamine (2.98 ml) 
and 9,10-dibromoanthracene (0.8g) were added to the reaction mixture, at room 
temperature, followed by addition of N-(butoxymethyl)acrylamide (3.38g). The mixture was 
heated at 90°C for 48hrs under nitrogen to complete of the reaction. The reaction was 
allowed to cool and dilute HCl (15 ml, 2M) was added. The resulting precipitate was filtered 
and washed with water (3x 20 ml) and diethyl ether (3x15 ml) and dried under vacuum 
afforded 60a as green solid; yield: (1.02g, 87%). 
1H NMR (400 MHz; d6-DMSO) δ= 0.89 (6H, t, J = 6.88 Hz, CH-9), 1.36 (4H,m-5, J = 7.71 
Hz, CH-8), 1.5 (4H, tt, J = 7.42, 6.45 Hz, CH-7), 3.49 (4H, t, J = 7.24 Hz, CH-6), 4.7 (4H, s, 
CH-5), 6.5 (2H, d, J = 16.04 Hz, CH-4), 7.6 (4H, ddd, J = 7, 3.8, 3.1 Hz, CH-3), 8.2 (4H, 
ddd, J = 6.81, 3.23, 3.46 Hz, CH-2).8.3 (2H,d, J = 16.05 Hz, CH-1) 
13C-NMR (400 MHz; d6-DMSO) δ= 13.8, 19.3, 31.8, 68.4, 70.3, 119.7, 126.4, 126.6, 129.7, 
130.6, 133.2, 163.7 
IR (ATR): v= 3279.77, 1658.76, 1551.60, 1247.83, 1135.69, 1110.44, 979.01.  


























Palladium acetate (119mg, 0.534mmol) and tri-(o-tolyl) phosphine (162.5mg, 0.534mmol) 
were placed in a Schlenk tube, followed by stirring in DMF (10ml) for 10 minutes at room 
temperature to generate the catalyst. After activating the catalyst, trimethylamine (2.98 ml) 
and 9,10-dibromoanthracene (0.8g) were added to the reaction mixture, at room 
temperature, followed by addition of N-(isobutoxymethyl)acrylamide (3.38g). The mixture 
was heated at 90°C for 48hrs under nitrogen to complete the reaction. The reaction was 
allowed to cool and dilute HCl (15 ml, 2M) was added. The resulting precipitate was filtered 
and washed with water (3x 20 ml) and diethyl ether (3x15 ml) and dried under vacuum 
afforded 60b as green solid; yield: (0.83g, 74%). 
 
1H NMR (400 MHz; d6-DMSO) δ= 0.8 (12H, d, J = 6.7 Hz, CH-8), 1.6 (2H, septt, J = 6.62, 
6.34 Hz, CH-7), 2.7 (4H,d, J=0.55Hz, CH-6), 2.8 (4H, s, CH-5), 6.5 (2H, d, J = 16.03 Hz, 
CH-1), 7.6 (4H,ddd, J = 6.8,3.25,3.17 Hz, CH-3), 8.24 (4H, ddd, J = 6.8,3.25,3.17 Hz, CH-
2),8.3(2H, d, J = 16.03 Hz, CH-4), 9.2 (2H, broad singlet, NH), 
 
13C-NMR (400 MHz; d6-DMSO) δ= 19.1, 28.1, 68.4, 70, 119.7, 126.3, 126.4, 129.7, 130.8, 
133.4 163.9 
IR (ATR): v= 3296.18, 1650.72, 1547.66, 1248.16, 1141.80, 1120.13, 992.67 













Palladium acetate (20.6mg, 0.092mmol) and triphenylphosphine (48.2mg, 0.184mmol) 
were placed in a Schlenk tube, followed by stirring in DMF (10ml) for 10 minutes at room 
temperature to generate the catalyst. After activating the catalyst, trimethylamine (0.225ml) 
and 1,3,5-tris(4-bromophenyl) benzene (1g) were added to the reaction mixture, at room 
temperature, followed by addition of 0.145ml of methyl acrylate. The mixture was heated at 
90°C for 72hrs under nitrogen to complete of the reaction. The reaction was allowed to cool 
and dilute HCl (15 ml, 2M) was added. The resulting precipitate was filtered and washed 
with water (3x 20 ml) and diethyl ether (3x15 ml) and dried under vacuum afforded 67 as 
white crystals; yield: (0.5g, 52%). 
1H NMR (400 MHz; d6-DMSO) δ= 3.7 (9H, s, CH-6), 6.7 (3H, d, J = 16.8 Hz, CH-5), 7.7 (3H, 
d, J = 16.3 Hz, CH-4), 7.8 (6H, d, J = 8.61 Hz, CH-3), 7.9 (6H, d, J = 8.2 Hz, CH-2), 8.0 (3H, 
s, CH-1). 
13C-NMR (400 MHz; d6-DMSO) δ= 51.485, 117.8, 124.723, 128.688, 128.918, 133.962, 
141.298, 142.146, 144.014, 145.071, 167.218 
IR (ATR): v= 2948.21, 1716.89, 1312.94, 1266.90. 


















Palladium acetate (23.79mg, 0.106mmol) and triphenylphosphine (55.6mg, 0.212mmol) 
were placed in a Schlenk tube, followed by stirring in DMF (10ml) for 10 minutes at room 
temperature to generate the catalyst. After activating the catalyst, N,N-
diisopropylethylamine (1.48ml)  and 3,3′,5,5′-tetrabromo-1,1′-biphenyl (0.25g)  were added 
to the reaction mixture, at room temperature, followed by addition of methyl acrylate 
(0.76ml). The mixture was heated at 90°C for 72hrs under nitrogen to complete the reaction. 
To the reaction mixture, EtOAc 20ml was added and the organic solution was washed with 
brine (20ml x 3) and LiCl (20ml x 3), then it was dried using Na2SO4. The organic residue 
was recrystallized from toluene to give 61a yield; (0.039g, 15%).  
1H NMR (400 MHz; d6-DMSO) δ= 3.7 (12H, s, CH-5), 6.9 (4H, d, J = 16.25 Hz, CH-3), 7.76 
(4H, d, J = 16.24, CH-1). 8.17 (2H, s, CH-2), 8.27 (4H, d, J = 1.26 Hz, CH-4) 
13C-NMR (400 MHz; d6-DMSO) δ= 51.6, 116.5, 121, 127.7, 132.3, 138, 144.4, 167.7 
IR (ATR): v= 2950.92, 1699.03, 1434.56, 1165.54, 846.59. 















































prop-1-enyl]phenyl]prop-2-enoate 61a (0.039g,79.5µM) compound was stirred with 4 
equivalence of KOH in Methanol and then the mixture was heated to 60 oC for 24 hours. 
After the TLC result, reaction was stopped and cooled down to room temperature. To this 
mixture 4M HCl (5ml) was added and resultant precipitate was filtered. (17mg, 46%). 
1H NMR (600 MHz; d6-DMSO) δ= 3.56 (6H, s, CH-1), 6.84 (4H, d, J=16.09 Hz, CH-5,8), 
7.07 (4H, d, J=16.11, CH-2,7), 7.57 (2H, dd, J = 2.0, 1.8 Hz, CH-4), 7.63 (2H, dd, J= 2.0, 
1.7 Hz, CH-3), 8.25 (2H, dd, J = 1.8, 1.7 Hz, CH-6), 12.48 (2H, s, OH-9)  
 
13C-NMR (600 MHz; d6-DMSO) δ= 51.57, 116.5, 119.7, 121.018, 127.6, 132.335, 138.027, 
144.42, 167.66, 168.226 
IR (ATR): v= 2922.05, 1698.17, 1633.45, 1166.61, 854.52. 
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Under a dry nitrogen atmosphere, triphenylphosphine (2.38 mmol, 624mg) and Pd (OAc)2 
(267mg) were added together in DMF (20 ml) in a Schlenk tube. After activation; 9,10-
dibromoanthracene (2.0 g, 5.9 mmol), acrylamide (2.143ml, 2.38mmol) and triethylamine 
(3.317mL, 2.38mmol) were added to the mixture. The reaction was heated up to 90oC and 
left to stir for 24 hrs. The completed reaction mixture was allowed to cool down to room 
temperature and diluted with HCl (15 ml, 2M). Dilution with HCl gave a green precipitate 
and then it was filtered. The filtrate was then washed with water (3x20ml) and diethyl ether 
(3x15ml). After this procedure, the green precipitate was recrystallised using methanol to 
give 60c bright green crystals; yield: (0.62g, 33%).    
1H NMR (600 MHz; d6-DMSO) δ= 3.8 (6H, s, CH-1), 6.4 (2H, d, J = 16.81 Hz, CH-2), 7.63 
(4H, ddd, J = 6.94, 6.47, 3.70 Hz, CH-3), 8.22 (4H, ddd, J = 6.67, 6.18, 3.45 Hz, CH-4), 8.55 
(2H, d, J = 16.25 Hz, CH-5) 
13C-NMR (600 MHz; d6-DMSO) δ= 51.6, 116.7, 126.7, 126.8, 129.7, 130.8, 133.4, 167.7 
IR (ATR): v= 2947.45, 1709.23, 1433.93, 997.69 























(E)-3-[10-[(E)-2-carboxyvinyl]-9-anthryl]prop-2-enoicacid 60c (140mg, 0.44mmol) and 
piperonylamine (103.6mg, 0.96mmol) were stirred in DCM (4ml) at room temperature under 
N2.To this solution mixture EDCI.HCl (185.4mg, 0.96mmol) and HOBt (130mg, 0.96mmol) 
in DCM (6ml) was added dropwise at 0°C. Then, DIPEA (0.34ml, 1.93mmol) was added 
dropwise to the solution mixture and was left to stir and reflux for 24h.  After completion of 
the reaction, the resulting precipitate was filtered and washed with water (3x 20 ml) and 
brine (20ml) and dried under vacuum to produce 52a a green solid; yield: (141mg, 55%). 
1H NMR (400 MHz; d6-DMSO) δ= 3.7 (4H, s, CH-5), 5.99 (4H, s, CH-8), 6.20 (2H,d, J= 
16.21, CH-3)6.79 (2H, d, J = 2.53 Hz, CH-6),6.82 (2H,s, CH-9), 6.85 (2H,d, J = 1.41 Hz, 
CH-7),7.61 (4H, ddd, J = 6.65, 3.49, 3.18 Hz, CH-2), 8.24 (4H, ddd, J = 6.98, 3.42, 3.25 Hz, 
CH-1), 8.29 (2H, d, J = 16.37 Hz, CH-4) 
13C-NMR (400 MHz; d6-DMSO) δ= 43.7,101.5,108.1,108.9,119.7,126.7,126.9,127.4,129.5 
130.6,133.4,133.6,147.7,147.9,167.2 
IR (ATR): v= 3272.15, 2920.37,  
HR MS (ES) m/z = found 585.2025, requires 585.6313 [M + H]+ 
MP=243-245oC 
 








 (E)-3-[10-[(E)-2-carboxyvinyl]-9-anthryl]prop-2-enoic acid 60c (140mg, 0.44mmol) and 4-
(aminomethyl)pyridine (190.2mg, 1.76mmol) were stirred in DCM (4ml) at room temperature 
under N2.To this solution mixture EDCI.HCl (337.4mg, 1.76mmol) and HOBt (238mg, 
1.76mmol) in DCM (6ml) was added dropwise at 0°C. Then, DIPEA (0.612ml, 3.51mmol) 
was added dropwise to the solution mixture and was left to stir and reflux for 24h. After 
completion of the reaction, the resulting precipitate was filtered and washed with water (3x 
20 ml) and brine (20ml) and dried under vacuum to produce 52c a green solid; yield: 
(141.5mg, 65%).  
1H NMR (400 MHz; d6-DMSO) δ= 3.8 (4H, s, CH-5), 6.2 (2H, d, J = 16.25 Hz, CH-4), 7.04 
(4H, d, J= 1.23 Hz, CH-3), 7.61 (4H, dd, J = 6.85, 3.15 Hz, CH-2), 8.15 (4H, dd, J = 6.65, 
3.33 Hz, CH-1), 8.24 (2H, d, J = 16.05 Hz, CH-6) 
13C-NMR (400 MHz; d6-DMSO) δ= 40.73, 122.36, 123.41, 126.75, 127.31, 128.83, 131.05, 
136.85, 149.44, 156.64 
IR (ATR): v= 3285.03, 2971.91, 1624.16, 1650.77, 1605.86,1566.30 
HR MS (ES) m/z = found 499.2131, requires 499.5814 [M+H]+ 
MP=324-326oC 
 









A solution of ester (methyl (E)-3-[4-[3,5-bis[4-[(E)-3-methoxy-3-oxo-prop-1-
enyl]phenyl]phenyl]phenyl]prop-2-enoate) 67 compound 285mg was dissolved in a mixture 
of THF (5ml) and distilled  water (5ml). To this mixture, KOH (100mg) pellets were added. 
The reaction mixture was placed under reflux for 12hrs. The mixture was monitored via TLC 
using a 1:1 EtOAc and hexane solvent system. The resultant reaction mixture was diluted 
with 3M HCl and the white precipitate formed was filtered to produce 67a a white solid 
(213mg, 81%). The mass after subsequent modifications of the resulted compound was 
unfortunately not high enough for Mass spec. analysis.  
1H NMR (400 MHz; d6-DMSO) δ= 6.63 (3H, d, J=16.01 Hz, CH-1), 7.68 (3H, d, J=16.07, 
CH-3), 7.8 (6H , d, J=8.39, CH-2) 7.97 (6H, d, J =8.38, CH-4), 8.02(3H, s, CH-5), 12.43 (3H, 
s, OH-6) 
13C-NMR (400 MHz; d6-DMSO) δ=127.162, 133.4, 141.00571, 142.31, 125.11, 139.05797, 
127.05, 119.71464, 168.2265 
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A solution of methyl (E)-3-[10-[(E)-3-methoxy-3-oxo-prop-1-enyl]-9-anthryl]prop-2-enoate 
(60c) (285mg) was dissolved in a mixture of THF(5ml) and distilled water (5ml). To this 
mixture, KOH pellets (100mg) were added. The reaction mixture was placed under reflux 
for 12hrs. The mixture was monitored via TLC using a 1:1 EtoAc and hexane solvent 
system. The resultant reaction mixture was diluted with 3M HCl and the white precipitate 
formed was filtered to produce 60d a white solid; yield: (0.11g, 42%). 
 
1H NMR (400 MHz; d6-DMSO) δ=6.32 (2H, d, J= 16.06 Hz, CH-4), 7.64 (4H, dd, J = 6.83, 
3.30 Hz, CH-2), 8.22 (4H, dd, J = 6.80, 3.34 Hz, CH-1), 8.48 (2H, d, J= 16.18 Hz, CH-
3),12.86 (2H, s, OH-5) 
13C-NMR (400 MHz; d6-DMSO) δ=  116.7, 126.7, 126.8, 129.7, 130.8, 133.4, 167.7 
IR (ATR): v= 2971.63, 1683.00, 1628.15, 1441.91,1421.05 
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A solution of ester 60c (15.5mg,0.045mmol) in dry DCM (4ml) was cooled to -78oC followed 
by dropwise addition of diisobutylaluminum hydride (1.5 M in toluene, 33µL, 0.049mmol). 
Reaction was stirred at -78oC for 30 minutes, then quenched with methanol (2ml) and 
saturated aqueous Rochelle’s salt solution (5ml). The aqueous phase was then extracted 
by dichloromethane (3x5ml) and organic phases dried over sodium sulphate. *This 
procedure was used to oxidize ester compound 60c to aldehyde 69 however the reaction 
was reduced to alcohol 70 yield: (11.5mg, 0.043mmol, 95%). 
1H NMR (400 MHz; d6-CDCl3) δ=7.40 (4H, dd, J=6.96, 3.29 Hz, CH-2), 8.24 (4H, dd, J= 
6.67, 3.45 Hz, CH-1) 
13C-NMR (400 MHz; d6-CDCl3) δ= 126.8, 128.1, 129.6, 130.8, 170.1 
IR (ATR): v= 3290.48, 2920.32, 1437.26, 1368.39 





















1-(2-Aminoethyl) piperidine (0.35ml, 314mg, 0.0024mol) and 9-10dibromocarbaldehyde 
(250mg) were stirred in dry DCM (40ml) over molecular sieves. The reaction mixture was 
refluxed for 12 hrs under N2 environment. The resulted mixture was monitored via TLC 
which showed the consumption of both starting materials. After TLC analysis, the crude 
mixture was left to cool down to room temperature. The solid imine product 55c was filtered 
and it was dried under vacuum before being recrystallised from methanol to yield a yellow 
coloured 55c solid (0.32g, 65% yield) and then it was stored in 0oC. 
1H NMR (400 MHz;  d6-DMSO) δ= 9.3(2H, s, CH-3), 8.5(4H, ddd, J=6.90, 3.11, 1.90 Hz, 
CH-2), 7.52(4H, ddd, J=6.98, 3.22, 1.52, CH-1), 4.08(4H, t, J=6.96 Hz, CH-4), 2.86(4H, t, 
J=7.70 Hz, CH-5), 2.58(8H, broad, CH-6)  1.67(8H, quintet, J=5.46 Hz, CH-7) 1.5 (4H, t, 
J=6.32 Hz, CH-8) 
13C-NMR (400 MHz; d6-DMSO) δ= 24.1, 26.3, 50.9, 54.9, 55, 126.7, 127.4, 130.7, 130.9, 
159.9 
IR (ATR): v= 2924.30, 2791.03, 2849.60, 1640.34, 1437.78, 754.18 











Tryptamine (390mg, 0.00245mol) and 9-10dibromocarbaldehyde (250mg) were stirred in  
dry DCM (40ml)  over molecular sieves. The reaction mixture was refluxed for 12hrs under 
N2 environment. The resultant mixture was monitored via TLC which showed the 
consumption of both starting materials. After TLC analysis, the crude mixture was left to 
cool down to room temperature. The resulting yellow solid 55k was filtered and it was dried 
under vacuum before being recrystallised from methanol to give (0.44g, 80%) yield. 
1H NMR (400 MHz; d6-DMSO) δ= 3.68 (4H, t, J=6.65 Hz, CH-8) 4.26 (4H, t, J=8.66Hz, CH2-
7), 7.01 (2H, t, J=8.76Hz, CH-6), 7.10 (2H, t, J=8.78Hz, CH-5) 7.23(2H, s, CH-4),7.39 (2H, 
dddd, J = 8.0, 1.2, 0.5, 0.5 Hz*data book values, H-10), 7.424(4H, dd, J=6.63, 2.21 Hz, CH-
3), 7.695 (2H, d, J= 7.74Hz, CH-9), 8.123 (4H, dd, J=6.97,2.68, CH-2) 
*extensive overlap, leading to difficulty in assignment, therefore a nmr prediction package was used. 
(244)(247)(248). 
13C-NMR (600 MHz; d6-DMSO) δ=22.5, 46.9, 111.6, 112, 118.7, 120.2, 121.7, 122.2, 126.7, 
127.5, 127.6, 130.7, 130.8, 136.4, 159.9 
IR (ATR): v=2843.46, 2922.6, 1652.99, 1621.80, 741.77,755.12 
HR MS (ES) m/z = found 519.2541, requires 520.6642 [M+2H]+ 
MP=237-239oC 
 




anthryl]methyleneamino]phenyl]acetamide (55l)  
 
55l 
3′-Aminoacetanilide (360 mg, 0.00245mol) and 9-10dibromocarbaldehyde (250mg) were 
stirred in dry DCM (40ml) over molecular sieves. The reaction mixture was refluxed for 12hrs 
under N2 environment. The resultant mixture was monitored via TLC which showed the 
consumption of both starting materials. After TLC analysis, the crude mixture was left to 
cool down to room temperature. The resulting off white solid 55l was filtered and it was dried 
under vacuum before being recrystallised from methanol to give (190mg,35%) yield. 
1H NMR (400 MHz; d6-DMSO) δ= 2.09 (9H, s, CH-7), 7.245 (2H, d, J=6.34Hz, CH-6), 7.45 
(2H, dd, J=8.42, 7.16 Hz, CH-5), 7.58 (2H, s , CH-4), 7.71 (4H, dd, J=6.97,2.68, CH-2), 7.74 
(2H, ddd, J = 7.9, 7.4, 0.5 Hz*data booked values, CH-3) 8.73 (4H, dd, J=6.63, 2.21 Hz, 
CH-1) 
*extensive overlap, leading to difficulty in assignment, therefore a nmr prediction package 
was used (244)(247)(248). 
13C-NMR (600 MHz; d6-DMSO) δ= 24, 115, 119.1, 121.6, 126.7, 129.4, 130.7, 130.9, 137.5, 
143.7, 159.9, 168.4 
IR (ATR): v= 3279.68, 2864.19, 1620.19, 1653.88, 1442.34, 1000.36,1032.17 
HR MS (ES) m/z = found 499.2130, requires 499.5814 [M+H]+ 
MP=329-331o 









2-Amino-5-methylthiazole (500 mg, 0.0048mol) and 9,10-dibromocarbaldehyde (250mg) 
were stirred in dry DCM (40ml) over molecular sieves. The reaction mixture was refluxed 
for 12hrs under N2 environment. The resultant mixture was monitored via TLC which 
showed the consumption of both starting materials. After TLC analysis, the crude mixture 
was left to cool down to room temperature. The resulting red solid 55j was filtered and it 
was dried under vacuum before being recrystallised from methanol to give (0.34g, 75%) 
yield. 
1H NMR (400 MHz; d6-DMSO) δ= 1.23 (6H, s, CH3-5), 7.6 (2H, d, J=1.20Hz, CH-3), 7.77 
(4H, dd, J=6.85,3.24 Hz, CH-1), 8.78 (4H, dd, J=6.93,3.19Hz, CH-2), 10.22 (2H, s, CH-4) 
13C-NMR (400 MHz; d6-DMSO) δ=12.495, 124.2714, 128.264, 128.341, 129.366, 129.423, 
135.2327, 167.977, 196.115 
IR (ATR): v= 2919.38, 1677.56, 1577.16, 1440.95, 751.59 














3-Morpholinopropylamine (350 mg, 0.0024mol) and 9,10-dibromocarbaldehyde (250mg) 
were stirred in dry DCM (40ml) over molecular sieves. The reaction mixture was refluxed 
for 12hrs under N2 environment. The resultant mixture was monitored via TLC which 
showed the consumption of both starting materials. After TLC analysis, the crude mixture 
was left to cool down to room temperature. The resulting off white solid 55m was filtered 
and it was dried under vacuum before being recrystallised from methanol to give (0.31g, 
60%) yield. 
1H NMR (600 MHz; d6-DMSO) δ= 1.9 (4H, m(5), J=7.2Hz, CH-1), 2.29 (2H, s, *data booked 
values CH-2), 2.39 (4H, q, J=1.84Hz, CH-4), 2.52 (4H, t, J=1.90Hz, CH-3), 3.49 (4H, t, 
J=4.75Hz, CH-6), 3.62 (8H, t, J=4.69Hz, CH-5), 7.60 (4H, dd, J=6.69, 3.16 Hz, CH-7), 
8.5(4H, dd, J=7.24,3.24 Hz, CH-8) 
extensive overlap, leading to difficulty in assignment, therefore a nmr prediction package 
was used (244)(247)(248). 
13C-NMR (600 MHz; d6-DMSO) δ= 23.1, 46.9, 50.9, 54.1, 66.3, 126.7, 126.9, 130.7, 130.8, 
159.9 
IR (ATR): v= 2807.34, 2854.18, 1630.97, 1238.90, 1116.07. 
HR MS (ES) m/z = found 487.3073, requires 488.6623 [M+2H]+ 
MP=160-162oC 








Piperonylamine (370 mg, 0.00245mol) and 9,-10-dibromocarbaldehyde (250mg, moles) 
were stirred in dry DCM (40ml) over molecular sieves. The reaction mixture was refluxed 
for 12hrs under N2 environment. The resultant mixture was monitored via TLC which 
showed the consumption of both starting materials. After TLC analysis, the crude mixture 
was left to cool down to room temperature. The resulting yellow solid 55a was filtered and 
it was dried under vacuum before being recrystallised from methanol to give (0.42g, 78%) 
yield. 
1H NMR (600 MHz; d6-DMSO) δ= 5.03 (4H, s, CH-1), 6.02 (4H, s, CH-2), 6.9 (2H, dd, 
J=7.98, 0.42 Hz, CH-4), 6.98 (2H, dd, J=7.76, 1.66 Hz, CH-5), 7.08 (2H, dd, J=1.42, 0.28 
Hz, CH-3), 7.6(4H, dd, J=7.04, 3.31 Hz, CH-7), 8.54(4H, dd, J=7.01, 3.29 Hz, CH-8), 
9.62(2H, t, J=1.30Hz, CH-9) 
13C-NMR (600 MHz; d6-DMSO) δ= 65, 101.5, 108.1, 108.9, 125.42, 126.7, 127.6, 130.7, 
130.8, 137.5, 147.7, 147.9, 159.9 
IR (ATR): v= 2935.03, 1618.90, 1502.29,1488.79,765.11 
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6.2 Cell Culture Methods  
 
Incubation was carried out using Thermofisher Steri-Cycle CO2 incubators and for plate 
reading Thermofisher Epoch Microplate Spectrophotometer was used. Centrifugation was 
carried out using aThermo Scientific Sorvall ST 40 Centrifuge Series. 
6.2.1 Media Preparation  
 
Commercially available DMEM (Dulbecco’s Modified Eagle Medium- low glucose), including 
sodium pyruvate and α-glutamine, 500 mL, was obtained from Gibco, USA.  All procedures 
carried out under sterile conditions, 94 mL of medium was taken and the required volume 
of supplements (10 % Fetal Bovine Serum (FBS), 2 mM/mL Glutamine, 100 U/mL penicillin 
and 100 µg/mL streptomycin.)  were added. 
6.2.2 Cell Line and Cell Culture Conditions 
  
Human cervical cancer cell lines (HeLa) were obtained from the American Type Culture 
Collection (ATCC) (ATCC® CCL-2™).  
HeLa cells were cultured in Dulbecco’s Eagle Modified Medium low glucose (DMEM) 
containing 10 % Fetal Bovine Serum (FBS), 2 mM/mL Glutamine, 100 U/mL penicillin and 
100 µg/mL streptomycin.    
These cells were kept in media which was changed with fresh media every 2 days. All of 
the cells were cultured in a humidified incubator whose conditions are 37 o C, 5 % CO2, 95 
% air.   
6.2.3 Cell Passaging  
 
The cells were split when the cells reached 70 % confluency in the flask. First of all, the 
medium was removed from the flask and then cells were washed with DPBS (1X) (pH 7.4) 
containing 10 mM sodium dibasic phosphate, 2.7 mM KCI, 2 mM Potassium phosphate, 
137 mM NaCI. After that, the cells were detached from the flask with 0.25 % (w/v) trypsin- 
5mM EDTA in PBS (Phosphate Buffered Saline) solution and incubated for 5 minutes in an 
incubator with conditions at 37 oC, 5 % CO2, 95 % air. Dissociated cells were resuspended 
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with medium containing 10 % Fetal Bovine Serum (FBS) to inhibit the trypsin activity and 
then centrifuged at 1500rpm for 5 minutes. After centrifugation, the supernatant was 
discarded, and cells were resuspended with media and seeded into the flasks.  
6.2.4 Cell Counting and Viability 
 
In order to determine cell density a hemacytometer was used, with the following procedure. 
First of all, chamber and cover slip cleaned with 70 % IMS. After gentle drying, the coverslip 
was placed in position. 10 µL of the harvested cells in media (cell suspension) and a 10µl 
of a prepared 0.4% trypan blue in buffered isotonic salt solution (pH 7.2 – 7.3) were added 
to eppendorfs. 10µL of Eppendorf solution is then loaded into the hemacytometer. The 
chamber placed in the inverted microscope with 10x objective. Finally, the blue stained cells 
and total number of cells in the central gridded square were counted and the average 
number of cells per mL was estimated by applying this formula; 
       𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛= 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
  𝑥 10000 𝑥 𝑠𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
With cell viability calculated with the following equation, where 95% viability was the target 
for cells; 
 %𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 = (1 − (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑙𝑢𝑒 𝑐𝑒𝑙𝑙𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠
)) 𝑥 100 
6.2.5 Cell Freezing 
 
 Cells were trypsinized from the cell plate and then centrifuged as described previously in 
Section 3. After that, the supernatant was discarded and the pellet was resuspended with 
freezing medium, including 90% heat inactivated Fetal Bovine Serum (FBS) and 10 % 
Dimethyl Sulfoxide (DMSO). 1 ml of cell suspension were put into each cryovial and then 
frozen at -80 oC or kept in liquid nitrogen tank for long term preservation.   
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6.2.6 Cell Thawing   
 
Cryovials were taken from the liquid nitrogen tank and thawed quickly at 37 oC.  After that, 
the cell suspension was transferred to a 15 mL tube and 5 mL of the medium was added 
into the cell suspension drop by drop with gentle shaking.  Centrifugation was done at 
1500rpm for 5 min and then supernatant was discarded. After the pellet was resuspended 
with medium, they were seeded to T-25 flasks. Subsequent to 12 hours incubation, the 
media was removed and washed with DPBS (1X) (pH:7.4) containing 10 mM sodium dibasic 
phosphate, 2.7 mM KCI, 2 mM Potassium phosphate,137 mM NaCI. Fresh media was 
added to the cell monolayer a day later thawing. 
6.2.7 Seeding plates 
 
Assays were carried out using a 96 well plate. This 96-well plate contains one blank, 3 
controls which contains cells including a negative control with media, one vehicle control 
which is DMSO and medium solutions, and a positive control of Doxorubicin (200µL) and 
media. Drugs were prepared in 100, 30, 10, 1 µM concentrations to make 8 seeded well 
plates in total which were done in triplicate. All drugs were prepared in DMSO and then 
diluted in media to give 5µL of DMSO max in 100µM treatments which is controlled by 
vehicle with a DMSO volume of 5µL.  
6.2.8 Presto Blue Assay 
 
Cell suspension (200μl) containing 5000 healthy HeLa cells was seeded in 96-well plates 
(BDFalcon, Franklin Lakes, NJ) and allowed to attach and stabilize overnight at 37 °C with 
5% CO2. Aspiration of media and rinsing solution was done through pipetting off liquid. Cell 
viability was then tested with PrestoBlue assay. 
The presto blue assay was carried out in light sensitive conditions. 100μl of PrestoBlue 
solution (10% in medium) was added to each well and the plates were incubated at 37 °C 
for 1 hour. After incubation time, the change in florescence was measured at 570/600 nm 
using a Spectra Max fluorescence multi-well plate reader. 




6.2.9 NMR intercalation procedure  
 
NMR tubes used were Wilmad 5 mm, thin‐walled tubes obtained from GPE Scientific 
(Product No: 502‐7).  NMR samples were spiked with Sodium d4‐trimethylsilylpropionate 
(TSP) to a concentration of 10 mmol/L. All spectra were recorded in 0.6ml of H2O-D2O 
(90:10 v/v) solvent, with 25mM phosphate buffer, 150mM KCl and 1mM EDTA. 
Oligonucleotide d(TTAGGGT)4 was purchased from Sigma Aldrich and made up to a 
concentration of 0.4mM in the solvent mix. This oligonucleotide solvent mix was then micro-
pipetted at a volume of 0.6ml into NMR tubes. Stock solutions of drug compounds in DMSO 
were used to make up the molar ratios of 0.125:1, 0.25:1, 0.5:1 and 1:1 drug to oligomer. A 
non-active drug (53a) and DMSO on its own were added as controls to validate that the 
effects on the spectra were from cytotoxic elements of the drug compounds rather than the 
effects from DMSO or addition of compound, which could change environment, pH or 
shimming of NMR instrument. 
Spectra were acquired at 300 K using a Bruker Avance III 600MHz FT‐NMR. The 
WATERNOESY parameter set which executes the pulse sequence noesygppr1d (Bruker, 
size of fid 65536, 12335.526 Hz spectral width, 128 scans, d1 = 4 s) was used to acquire 
1H 1D experiments with a pre-saturation delay during relaxation and mixing time 
(experiment time: 14 min 44 sec). With this pulse sequence, all non-exchangeable protons 
are detected in the deuterated D2O/H2O buffer solution. T1 relaxation experiments were 
acquired for d1 calibration with a modified version of the zggpw5 pulse sequence. With a 
saturation recovery block (delays 0.01, 0.22, 0.54, 1.05, 1.84, 3.08, 5.01, 8.01, 12.69, 20.00 
s) before the first 90° pulse and using water suppression (Bruker, size of fid 65536/11 F2/F1, 
12335.526/5882.353 Hz spectral width in F2/F1, 64 scans, 0.1 s relaxation delay) 
(experimental time 1 h 4 min 6 sec). 
Bruker Topspin 3.5 pl7 was used for assignment of peaks, manual phasing, baseline 
correction and manual integration. Manual integration was done to ensure bias and slope 
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was correct and that the integrals were all of the same width. Calculation of chemical shift 
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